var title_f13_63_14320="Lymphocutaneous sporotrichosis leg";
var content_f13_63_14320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocutaneous sporotrichosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphocutaneous sporotrichosis on the right lower extremity of a young man who overturned his dirt bike and inoculated soil in multiple places in his leg. Following a plastic surgery procedure before the diagnosis of sporotrichosis, new lesions developed at the edge of the skin graft and extended up into the thigh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A. Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14320=[""].join("\n");
var outline_f13_63_14320=null;
var title_f13_63_14321="Flea bites ankle";
var content_f13_63_14321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flea bites ankle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four flea bites clustered on an ankle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14321=[""].join("\n");
var outline_f13_63_14321=null;
var title_f13_63_14322="TURP result";
var content_f13_63_14322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Prostate anatomy after transurethral resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 668px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following TURP, the prostatic fossa bound only by its capsule. The cavity will become lined with a regenerated surface in six to twelve weeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14322=[""].join("\n");
var outline_f13_63_14322=null;
var title_f13_63_14323="Sequestration aortogram I";
var content_f13_63_14323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An aortogram demonstrates the systemic supply of the left basilar sequestration. The splanchnic artery originates from the lower thoracic aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14323=[""].join("\n");
var outline_f13_63_14323=null;
var title_f13_63_14324="Maternal pelvic types";
var content_f13_63_14324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    The four maternal pelvic types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A line passing through the widest transverse diameter divides the inlet into posterior (P) and anterior (A) segments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.286.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14324=[""].join("\n");
var outline_f13_63_14324=null;
var title_f13_63_14325="Structure mevalonate kinase";
var content_f13_63_14325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tertiary structure of rat mevalonate kinase (MVK)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Monomer; B: Homodimer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fu, Z, Wang, M, Potter, D, et al. The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem 2002; 277:18134. Copyright &copy;2002 American Society for Biochemistry and Molecular Biology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14325=[""].join("\n");
var outline_f13_63_14325=null;
var title_f13_63_14326="LEVOleucovorin: Drug information";
var content_f13_63_14326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   LEVOleucovorin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/11/39091?source=see_link\">",
"    see \"LEVOleucovorin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6268764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fusilev&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6063703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Chemotherapy Modulating Agent;",
"     </li>",
"     <li>",
"      Rescue Agent (Chemotherapy)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6063905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Levoleucovorin, when substituted in place of leucovorin calcium (the racemic form), is dosed at",
"     <b>",
"      one-half",
"     </b>",
"     the usual dose of leucovorin calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer:",
"     </b>",
"     I.V.: The following regimens have been used (in combination with fluorouracil; fluorouracil doses may need to be adjusted for toxicity; no adjustment required for the levoleucovorin dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     100 mg /m",
"     <sup>",
"      2",
"     </sup>",
"     /day over at least 3 minutes (followed by fluorouracil 370 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 5 days every 4 weeks for 2 cycles, then every 4-5 weeks depending on recovery from toxicities,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10 mg /m",
"     <sup>",
"      2",
"     </sup>",
"     /day (followed by fluorouracil 425 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) for 5 days every 4 weeks for 2 cycles, then every 4-5 weeks depending on recovery from toxicities,",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Alternative dosing:",
"     </i>",
"     Levoleucovorin, when substituted in place of leucovorin calcium within a chemotherapy regimen, is dosed at",
"     <b>",
"      one-half",
"     </b>",
"     the usual dose of leucovorin calcium (Goldberg, 1997; NCCN colon cancer guidelines v.2.2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      High-dose methotrexate rescue:",
"     </b>",
"     I.V.: Usual dose: 7.5 mg (~5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) every 6 hours for 10 doses, beginning 24 hours after the start of the methotrexate infusion (based on a methotrexate dose of 12 g/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. over 4 hours). Levoleucovorin (and hydration and urinary alkalinization) should be continued and/or adjusted until the methotrexate level is &lt;0.05 micromolar (5 x 10",
"     <sup>",
"      -8",
"     </sup>",
"     M) as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Normal methotrexate elimination",
"     </i>",
"     (serum methotrexate levels ~10 micromolar at 24 hours post administration, 1 micromolar at 48 hours and &lt;0.2 micromolar at 72 hours post infusion): 7.5 mg I.V. every 6 hours for 10 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Delayed late methotrexate elimination",
"     </i>",
"     (serum methotrexate levels &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours post methotrexate infusion): Continue 7.5 mg I.V. every 6 hours until methotrexate level is &lt;0.05 micromolar",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Delayed early methotrexate elimination and/or evidence of acute renal injury",
"     </i>",
"     (serum methotrexate level &ge;50 micromolar at 24 hours, &ge;5 micromolar at 48 hours or a doubling or more of the serum creatinine level at 24 hours post methotrexate infusion): 75 mg I.V. every 3 hours until methotrexate level is &lt;1 micromolar, followed by 7.5 mg I.V. every 3 hours until methotrexate level is &lt;0.05 micromolar",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Significant clinical toxicity in the presence of less severe abnormalities in methotrexate elimination or renal function (as described above):",
"     </i>",
"     Extend levoleucovorin treatment for an additional 24 hours (total of 14 doses) in subsequent treatment cycles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Delayed methotrexate elimination due to third space fluid accumulation, renal insufficiency, or inadequate hydration:",
"     </i>",
"     May require higher levoleucovorin doses or prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Methotrexate overdose (inadvertent):",
"     </b>",
"     I.V.: 7.5 mg (~5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) every 6 hours; continue until the methotrexate level is &lt;0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M). Initiate treatment as soon as possible after methotrexate overdose. Increase the levoleucovorin dose to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. every 3 hours if the 24-hour serum creatinine has increased 50% over baseline, or if the 24 hour methotrexate level is &gt;5 micromolar (5 x 10",
"     <sup>",
"      -6",
"     </sup>",
"     M), or if the 48-hour methotrexate level is &gt;0.9 micromolar (9 x 10",
"     <sup>",
"      -7",
"     </sup>",
"     M); continue levoleucovorin until the methotrexate level is &lt;0.01 micromolar (10",
"     <sup>",
"      -8",
"     </sup>",
"     M). Hydration (aggressive) and urinary alkalinization (with sodium bicarbonate) should also be maintained.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6063904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Levoleucovorin, when substituted in place of leucovorin calcium (the racemic form),  is dosed at",
"     <b>",
"      one-half",
"     </b>",
"     the usual dose of leucovorin calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      High-dose methotrexate rescue:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Methotrexate overdose (inadvertent):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6063906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6063912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fusilev&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6063701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6063907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only; do not administer intrathecally. Administer by slow I.V. push or infusion over at least 3 minutes, not to exceed 160 mg/minute (due to calcium content).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For colorectal cancer: Levoleucovorin has also been administered (unlabeled administration rate) as I.V. infusion over 2 hours (Comella, 2000; Tournigand, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6063895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Granisetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6063705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced, metastatic colorectal cancer (palliative) in combination with fluorouracil; rescue agent after high-dose methotrexate therapy in osteosarcoma; antidote for impaired methotrexate elimination and for inadvertent overdosage of folic acid antagonists",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6063697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       LEVOleucovorin may be confused with leucovorin calcium, Leukeran&reg;, Leukine&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6063884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported with levoleucovorin either as a part of combination chemotherapy or following chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (&le;29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermatitis (6% to 29%), alopecia (&le;26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Stomatitis (38% to 72%; grades 3/4: 6% to 12%), diarrhea (6% to 70%; grades 3/4: &le;19%), nausea (19% to 62%), vomiting (38% to 40%), anorexia/appetite decreased (&le;24%), abdominal pain (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness/malaise (&le;29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Confusion (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (6%), taste perversion (6%), typhlitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Neuropathy (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal function abnormal (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, pruritus, rash, rigors, temperature changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6063712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of prior allergic reaction to folic acid or leucovorin calcium (folinic acid)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6063713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizure/syncope: Seizures and/or syncope have been reported with leucovorin calcium; generally in patients with CNS metastases or other underlying risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluorouracil: The toxicity of fluorouracil is enhanced by leucovorin calcium and levoleucovorin. Deaths due to severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin calcium in combination with fluorouracil. Levoleucovorin is indicated in combination with fluorouracil for the palliative treatment of colorectal cancer; when administered together, the fluorouracil dose is reduced (compared to fluorouracil dosing without levoleucovorin). The typical fluorouracil gastrointestinal toxicities (eg, diarrhea, stomatitis) may be of greater severity or longer duration with fluorouracil and levoleucovorin combination therapy. Symptoms of gastrointestinal toxicity should be completely resolved prior to treatment (initial or repeat).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfamethoxazole-trimethoprim: Concomitant use of leucovorin calcium and sulfamethoxazole-trimethoprim for the acute treatment of PCP in patients with HIV infection has been associated with increased rates of treatment failure and morbidity; may also occur with levoleucovorin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Elderly and/or debilitated patients are at higher risk for severe gastrointestinal toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Administration: For I.V. administration only; do not administer intrathecally. Due to calcium content, do not administer I.V. solutions at a rate &gt;160 mg levoleucovorin/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Levoleucovorin is not approved for and should not be used to treat pernicious anemia or megaloblastic anemias secondary to vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency; improper use may induce hematologic remission with progressive neurologic manifestations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of levoleucovorin therapy. Dose may need to be increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6063888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Capecitabine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6063707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6063708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Levoleucovorin is the levo isomeric form of racemic leucovorin, a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6063710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6063711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. Levoleucovorin is the levo isomeric form of racemic leucovorin, a biologically active form of folic acid. Adequate amounts of folic acid are recommended in breast-feeding women. Refer to Folic Acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fusilev Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $240.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6063909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High-dose methotrexate therapy or methotrexate overdose (inadvertent): Serum methotrexate and creatinine levels at least once daily. Monitor fluid and electrolyte status in patients with delayed methotrexate elimination (likely to experience renal toxicity).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elvorine (BE);",
"     </li>",
"     <li>",
"      Isovorin (AT, CH, DK, FI, GB, GR, NL, NO, PT, SE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6063896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Levoleucovorin counteracts the toxic (and therapeutic) effects of folic acid antagonists (eg, methotrexate) which act by inhibiting dihydrofolate reductase. Levoleucovorin is the levo isomeric and pharmacologic active form of leucovorin (levoleucovorin does not require reduction by dihydrofolate reductase). A reduced derivative of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Leucovorin enhances the activity (and toxicity) of fluorouracil by stabilizing the binding of 5-fluoro-2&rsquo;-deoxyuridine-5&rsquo;-monophosphate (FdUMP; a fluorouracil metabolite) to thymidylate synthetase resulting in inhibition of this enzyme.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6063898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Converted to the active reduced form of folate, 5-methyl-tetrahydrofolate (5-methyl-THF; active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 15 mg: 5-7 hours; 300 mg: elimination half life: 16-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: I.V.: 0.9 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Comella P, De Vita F, Mancarella S, et al, &ldquo;Biweekly Irinotecan or Raltitrexed Plus 6S-Leucovorin and Bolus 5-Fluorouracil in Advanced Colorectal Carcinoma: A Southern Italy Cooperative Oncology Group Phase II-III Randomized Trial,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11(10):1323-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/11106123/pubmed\" id=\"11106123\" target=\"_blank\">",
"        11106123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falcone A, Ricci S, Brunetti I, et al, &ldquo;Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(13):1670-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/17470860 /pubmed\" id=\"17470860 \" target=\"_blank\">",
"        17470860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg RM, Hatfield AK, Kahn M, et al, &ldquo;Prospectively Randomized North Central Cancer Treatment Group Trial of Intensive-Course Fluorouracil Combined With the l-Isomer of Intravenous Leucovorin, Oral Leucovorin, or Intravenous Leucovorin for the Treatment of Advanced Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(11):3320-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/9363861/pubmed\" id=\"9363861\" target=\"_blank\">",
"        9363861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goorin A, Strother D, Poplack D, et al, &ldquo;Safety and Efficacy of l-leucovorin Rescue Following High-Dose Methotrexate for Osteosarcoma,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1995, 24(6):362-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/7715542/pubmed\" id=\"7715542\" target=\"_blank\">",
"        7715542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hempel G, Lingg R, and Boos J, &ldquo;Interactions of Carboxypeptidase G2 With 6S-Leucovorin and 6R-Leucovorin",
"      <i>",
"       in vitro",
"      </i>",
"      : Implications for the Application in Case of Methotrexate Intoxications,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2005, 55(4):347-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/15723260/pubmed\" id=\"15723260\" target=\"_blank\">",
"        15723260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaffe N, Jorgensen K, Robertson R, et al, &ldquo;Substitution of l-leucovorin for d,l-leucovorin in the Rescue from High-Dose Methotrexate Treatment in Patients With Osteosarcoma,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 1993, 4(5):559-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/8292813/pubmed\" id=\"8292813\" target=\"_blank\">",
"        8292813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Labianca R, Cascinu S, Frontini L, et al, &ldquo;High-Versus Low-Dose Levo-Leucovorin as a Modulator of 5-Fluorouracil in Advanced Colorectal Cancer: A &lsquo;GISCAD&rsquo; Phase III Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1997, 8(2):169-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/9093726/pubmed\" id=\"9093726\" target=\"_blank\">",
"        9093726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mader RM, Steger GG, Rizovsky B, et al, &ldquo;Pharmacokinetics of Rac-Leucovorin vs [S]-Leucovorin in Patients With Advanced Gastrointestinal Cancer,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1994, 37(3):243-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/8198932/pubmed\" id=\"8198932\" target=\"_blank\">",
"        8198932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Colon Cancer,&rdquo; Version 2.2013. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheithauer W, Kornek G, Marczell A, et al, &ldquo;Fluorouracil Plus Racemic Leucovorin Versus Fluorouracil Combined With the Pure L-Isomer of Leucovorin for the Treatment of Advanced Colorectal Cancer: A Randomized Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(3):908-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/9060527/pubmed\" id=\"9060527\" target=\"_blank\">",
"        9060527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tournigand C, Cervantes A, Figer A, et al, &ldquo;OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer--A GERCOR Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):394-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/63/14326/abstract-text/16421419/pubmed\" id=\"16421419\" target=\"_blank\">",
"        16421419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10324 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14326=[""].join("\n");
var outline_f13_63_14326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6268764\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063905\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063904\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063906\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265589\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265590\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063912\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063701\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063907\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063895\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063705\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063697\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063884\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299596\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063888\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063707\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063708\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063710\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063711\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322879\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063909\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875343\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063896\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063898\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/11/39091?source=related_link\">",
"      LEVOleucovorin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_63_14327="Cluster headache: Epidemiology, clinical features, and diagnosis";
var content_f13_63_14327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cluster headache: Epidemiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14327/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14327/contributors\">",
"     Arne May, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14327/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14327/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14327/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14327/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/63/14327/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache belongs to a group of idiopathic headache entities, the trigeminal autonomic cephalalgias (TACs), all of which involve short-lasting, unilateral, severe headache attacks and typical accompanying autonomic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Cluster headache is the most prominent of these entities. The concept of the TACs is useful for clinicians seeking a pathophysiologic understanding of the primary neurovascular headaches and a rational therapeutic approach to treating or preventing these headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review focuses on the epidemiology, clinical features, and diagnosis of cluster headache. Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"     \"Cluster headache: Acute and preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of cluster headache is complex and remains incompletely understood. The most widely accepted theory is that primary cluster headache is characterized by hypothalamic activation with secondary activation of the trigeminal-autonomic reflex, probably via a trigeminal-hypothalamic pathway (",
"    <a class=\"graphic graphic_figure graphicRef81378 \" href=\"UTD.htm?34/57/35733\">",
"     figure 1",
"    </a>",
"    ). Another theory holds that neurogenic inflammation of the walls of the cavernous sinus obliterates venous outflow and thus injures the traversing sympathetic fibers of the intracranial internal carotid artery and its branches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of cluster headache is &lt;1 percent and mostly affects men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In a meta-analysis of 16 population-based epidemiologic studies, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lifetime prevalence of cluster headache for adults of all ages was 124 per 100,000 (95% CI 101-154), or approximately 0.1 percent",
"     </li>",
"     <li>",
"      The one year prevalence of cluster headache was 53 per 100,000 (95% CI 26-95)",
"     </li>",
"     <li>",
"      The overall male to female ratio was 4.3:1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some evidence that the male preponderance in cluster headache is decreasing, particularly in patients with headache onset after 1960 or 1970 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The probable explanation is improved understanding of the pathophysiology of this syndrome and consequently a higher acceptance and awareness leading to more frequent diagnosis. However, this finding has not been confirmed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have noted an apparently high incidence of head trauma in patients with cluster headache. As an example, one study of 374 patients found a history of head injury prior to cluster headache onset in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/10\">",
"     10",
"    </a>",
"    ]. However, such an association does not establish a cause-and-effect relationship. In addition, the average time between head injury and cluster headache onset (10 years) seems too long to support a causative role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before 1990, cluster headache was not thought of as an inherited disorder. However, the importance of considering genetic factors in the etiology is highlighted by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of monozygotic twins, both had cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epidemiologic studies have reported a family history of cluster headache in 5 to 20 percent of patients with cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/4,12-14\">",
"       4,12-14",
"      </a>",
"      ]. Compared with the general population, the risk of cluster headache for first-degree relatives was increased by 14 to 39-fold, and for second-degree relatives by two to eight-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence of increased familial risk supports the hypothesis that cluster headache has a genetic component, at least in some families.",
"   </p>",
"   <p>",
"    Results of a complex segregation analysis in one study suggested that an autosomal dominant gene may play a role in cluster headache inheritance in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/15\">",
"     15",
"    </a>",
"    ], although there is also evidence for autosomal recessive or multifactorial inheritance in others [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/3\">",
"     3",
"    </a>",
"    ]. Future studies must take into account that cluster headache can start between the age of 7 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/16\">",
"     16",
"    </a>",
"    ] and 83 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/17\">",
"     17",
"    </a>",
"    ] and that the distinction between affected and unaffected individuals is clearly provisional.",
"   </p>",
"   <p>",
"    Another issue concerns evidence that up to 85 percent of patients with cluster headache are also chronic cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/10\">",
"     10",
"    </a>",
"    ]. Quitting smoking has no effect on the disease. However, smoking may be a risk factor for the development of cluster headache, possibly on the basis of a genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/18\">",
"     18",
"    </a>",
"    ]. A study of clinically-detected cluster headache showed a marked decline in the incidence of cluster headaches between 1979-81 and 1990-91 in Olmsted County, Minnesota, during a time when the incidence of smoking declined in the population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache is characterized by attacks of severe orbital, supraorbital, or temporal pain, accompanied by autonomic phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ]. The stereotypical attacks may strike up to eight times a day and are relatively short-lived. Cluster headache is strictly unilateral, and the symptoms remain on the same side of the head during a single cluster attack. However, the symptoms can switch to the other side during a different cluster attack (so-called side shift) in approximately 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to migraineurs, patients with cluster are restless and prefer to pace about or sit and rock back and forth. The attacks of cluster headache can be so vicious that patients may commit suicide if the disease is not diagnosed or treated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autonomic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unilateral autonomic symptoms, such as ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion, occur only during the pain attack and are ipsilateral to the pain. These symptoms are indicative of both parasympathetic hyperactivity and sympathetic impairment. In some patients, the signs of sympathetic paralysis (miosis and ptosis) persist indefinitely [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/22\">",
"     22",
"    </a>",
"    ], but intensify during attacks. Sweating and cutaneous blood flow also increase on the painful side, particularly in areas of sympathetic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 3 percent of all patients lack autonomic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/25\">",
"     25",
"    </a>",
"    ]. In rare cases, sympathetic disturbances persist on the previously-affected side of the face in patients whose cluster headache has switched sides [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Circadian periodicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another clinical landmark of the cluster headache syndrome is the circadian rhythmicity of the relatively short-lived (15 to 180 minutes) painful attacks. In the episodic form, attacks occur daily for some weeks followed by a period of remission. In the chronic form, attacks occur without significant periods of remission. On average, a cluster period lasts 6 to 12 weeks while remissions can last up to 12 months or longer.",
"   </p>",
"   <p>",
"    The episodic form is the most common, affecting 80 to 90 percent of patients with cluster headache. It is characterized by periods of attacks (clusters or bouts) and periods of remission. In a bout, patients may experience one to eight attacks per day, and bouts may last from seven days to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ]. When not in a bout, patients are usually asymptomatic.",
"   </p>",
"   <p>",
"    The chronic form of cluster headache lacks remissions and is diagnosed after a year without remission, or if remission has lasted less than 30 days. Chronic cluster may arise de novo (primary chronic cluster headache) or evolve from the episodic type (secondary chronic cluster headache).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cluster headache, in its typical form, is unmistakable. The diagnosis is exclusively a clinical task based upon a compatible history and diagnostic criteria from the second edition of the International Classification of Headache Disorders (ICHD-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No single instrumental examination is able to define, ensure, or differentiate idiopathic headache syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, neuroimaging is suggested to exclude a cranial lesion in patients with suspected cluster headache. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary cluster headache'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the diagnosis of cluster headache, the ICHD-2 requires at least five headache attacks fulfilling the following criteria (",
"    <a class=\"graphic graphic_table graphicRef80843 \" href=\"UTD.htm?12/58/13228\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe or very severe unilateral orbital, supraorbital,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      temporal headache attacks, which last untreated for 15 to 180 minutes. During part (but less than half) of the time course of the cluster headache, attacks may be less severe, less frequent, or of shorter or longer duration.",
"     </li>",
"     <li>",
"      The headache is accompanied by at least one of the following symptoms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ipsilateral conjunctival injection or lacrimation",
"     </li>",
"     <li>",
"      Ipsilateral nasal congestion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rhinorrhea",
"     </li>",
"     <li>",
"      Ipsilateral eyelid edema",
"     </li>",
"     <li>",
"      Ipsilateral forehead and facial sweating",
"     </li>",
"     <li>",
"      Ipsilateral miosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ptosis",
"     </li>",
"     <li>",
"      A sense of restlessness and agitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The attacks have a frequency from one every other day to eight per day.",
"     </li>",
"     <li>",
"      The history and physical and neurologic examinations do not suggest any other disorder,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      such a disorder is ruled out by appropriate investigations, or such disorder is present but attacks do not occur for the first time in close temporal relation to the disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Attacks fulfilling all but one of the criteria for cluster headache are diagnosed as probable cluster headache.",
"   </p>",
"   <p>",
"    The ICHD-2 diagnostic criteria for episodic and chronic cluster headache are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic cluster headache is diagnosed when at least two cluster periods lasting seven days to one year are separated by pain free periods lasting one month or longer.",
"     </li>",
"     <li>",
"      Chronic cluster headache is diagnosed when attacks occur for more than one year without remission or with remission for less than one month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, patients with atypical or even typical clinical features of cluster headache are found to have a potential secondary cause for headache, such as a structural brain lesion. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Secondary cluster headache'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, for the initial diagnosis of patients with suspected cluster headache, including those with typical features, we suggest neuroimaging with a cranial CT scan or a cranial MRI study to exclude abnormalities of the brain and pituitary gland.",
"   </p>",
"   <p>",
"    We recommend neuroimaging for patients with an abnormal neurologic examination or those with clinical suspicion for a pituitary abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory examinations, including electrophysiologic testing (eg, evoked potential, electroencephalography) and examination of the cerebrospinal fluid, are not helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cluster headache involves consideration of headache syndromes that manifest with strictly unilateral, brief but frequent attacks (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 2",
"    </a>",
"    ). Such syndromes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal hemicrania",
"     </li>",
"     <li>",
"      Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT syndrome)",
"     </li>",
"     <li>",
"      Trigeminal neuralgia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"       \"Trigeminal neuralgia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary stabbing headache (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"       \"Primary stabbing headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Headache associated with an underlying intracranial lesion (ie, secondary cluster headache)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted earlier, cluster headache, paroxysmal hemicrania and SUNCT syndrome belong to a group of idiopathic headache entities, the trigeminal autonomic cephalalgias (TACs), which involve activation of trigeminovascular nociceptive pathways and reflex cranial autonomic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"     1",
"    </a>",
"    ]. All of the TACs have two features in common:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brief, unilateral, severe headache attacks",
"     </li>",
"     <li>",
"      Typical autonomic accompanying symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TACs differ in attack duration, frequency, and rhythmicity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/28\">",
"     28",
"    </a>",
"    ] and in the intensity of pain and autonomic symptoms (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 2",
"    </a>",
"    ). They also differ with regard to treatment options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Paroxysmal hemicrania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania is a rare condition with a female predominance. It is estimated that the paroxysmal hemicranias comprise about 3 to 6 percent of all the trigeminal autonomic cephalalgias. The headache usually starts between the ages of 20 and 40. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The paroxysmal headache attacks, the character and localization of the pain, and the autonomic symptoms are very similar to those observed in cluster headache (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 2",
"    </a>",
"    ). However, typical attacks of paroxysmal hemicrania are shorter (2 to 30 minutes) and more frequent (more than five attacks per day) than cluster attacks. In addition, the autonomic symptoms are often less severe than in cluster headache. About 80 percent of patients with paroxysmal hemicrania have the chronic form, while the remaining 20 percent have the episodic form. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important criterion for the diagnosis of paroxysmal hemicrania is the complete response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58505 \" href=\"UTD.htm?11/2/11308\">",
"     table 3",
"    </a>",
"    ). Within one week (often within three days) after the initiation of indomethacin at an adequate dose, the attacks disappear and this effect is maintained long-term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=see_link\">",
"     \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=see_link\">",
"     \"Paroxysmal hemicrania: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     SUNCT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The name of this syndrome (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing) describes its typical clinical features. SUNCT syndrome is rare, although its true frequency is unclear. SUNCT may be a subset of another proposed headache called short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SUNCT syndrome is characterized by very short (5 to 240 seconds) attacks with neuralgiform pain quality and severe intensity. The attacks occur at a frequency of 60 (3 to 200) per day on average, are strictly unilateral (periorbital), and are often triggered by touching, speaking, or chewing. When triggered, SUNCT attacks generally do not have a refractory period. The autonomic symptoms are mostly restricted to lacrimation and conjunctival injection. The diagnostic criteria are listed (",
"    <a class=\"graphic graphic_table graphicRef74387 \" href=\"UTD.htm?14/4/14412\">",
"     table 4",
"    </a>",
"    ). Distinct episodic and chronic forms of SUNCT syndrome are yet to be recognized in formal classifications, but both types occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important differential diagnosis for SUNCT is classic trigeminal neuralgia. In trigeminal neuralgia, unlike in SUNCT syndrome, autonomic symptoms are not prominent and triggered attacks have a clear refractory period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Secondary cluster headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated cranial lesions have been reported in patients with clinical attacks that resemble cluster headache, although a causal relationship is often uncertain. One review identified 31 reports of patients with a clinical picture suggesting one of the trigeminal autonomic cephalalgias, including 21 thought to have cluster headache, who turned out to have an associated structural lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/30\">",
"     30",
"    </a>",
"    ]. These lesions included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intracranial large artery aneurysms",
"     </li>",
"     <li>",
"      Meningiomas",
"     </li>",
"     <li>",
"      Brain arteriovenous malformations",
"     </li>",
"     <li>",
"      Pituitary macroadenomas",
"     </li>",
"     <li>",
"      Recurrent nasopharyngeal carcinoma",
"     </li>",
"     <li>",
"      Metallic foreign body in the maxillary sinus",
"     </li>",
"     <li>",
"      Aspergilloma in sphenoid sinus",
"     </li>",
"     <li>",
"      Benign posterior fossa tumor",
"     </li>",
"     <li>",
"      Cavernous hemangioma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each case, the headache improved after treatment of the lesion, suggesting but not proving a causal role for the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14327/abstract/30\">",
"     30",
"    </a>",
"    ]. Given that the headaches were often without atypical features, the results of this study suggest that all patients with symptoms of cluster headaches should have neuroimaging to exclude a cranial lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of cluster headache is complex and remains incompletely understood. The most widely accepted theory is that primary cluster headache is characterized by hypothalamic activation with secondary activation of the trigeminal-autonomic reflex, probably via a trigeminal-hypothalamic pathway (",
"      <a class=\"graphic graphic_figure graphicRef81378 \" href=\"UTD.htm?34/57/35733\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lifetime prevalence of cluster headache is &lt;1 percent, and the disorder mainly affects men. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accumulating evidence supports the hypothesis that cluster headache has a genetic component, at least in some families. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cluster headache is characterized by attacks of severe unilateral orbital, supraorbital, or temporal pain, accompanied by autonomic phenomena. Unilateral autonomic symptoms are ipsilateral to the pain and may include ptosis, miosis, lacrimation, conjunctival injection, rhinorrhea, and nasal congestion. Attacks usually last 15 to 180 minutes. In the episodic form, attacks can occur daily, usually one to eight times a day for some weeks, followed by a period of remission. The chronic form of cluster headache lacks sustained remissions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cluster headache, in its typical form, is unmistakable. The diagnosis is exclusively a clinical one (",
"      <a class=\"graphic graphic_table graphicRef80843 \" href=\"UTD.htm?12/58/13228\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occasionally, patients with atypical or even typical clinical features of cluster headache are found to have a potential secondary cause, such as a structural brain lesion. For patients with suspected cluster headache, we suggest neuroimaging with a cranial CT scan or a cranial MRI study to exclude abnormalities of the brain and pituitary gland. We recommend neuroimaging for patients with an abnormal neurologic examination or those with clinical suspicion for a pituitary abnormality. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Secondary cluster headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of cluster headache involves consideration of other unilateral, brief but frequent headaches (",
"      <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"       table 2",
"      </a>",
"      ), including the following (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Paroxysmal hemicrania",
"     </li>",
"     <li>",
"      Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT syndrome)",
"     </li>",
"     <li>",
"      Trigeminal neuralgia",
"     </li>",
"     <li>",
"      Primary stabbing headache",
"     </li>",
"     <li>",
"      Headache associated with an underlying intracranial lesion (ie, secondary cluster headache)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/2\">",
"      Nesbitt AD, Goadsby PJ. Cluster headache. BMJ 2012; 344:e2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/3\">",
"      Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol 2004; 3:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/4\">",
"      Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology 2002; 58:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/5\">",
"      Sjaastad O, Bakketeig LS. Cluster headache prevalence. V&aring;g&aring; study of headache epidemiology. Cephalalgia 2003; 23:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/6\">",
"      Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 2008; 28:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/7\">",
"      Ekbom K, Svensson DA, Tr&auml;ff H, Waldenlind E. Age at onset and sex ratio in cluster headache: observations over three decades. Cephalalgia 2002; 22:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/8\">",
"      Manzoni GC. Gender ratio of cluster headache over the years: a possible role of changes in lifestyle. Cephalalgia 1998; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/9\">",
"      Lin KH, Wang PJ, Fuh JL, et al. Cluster headache in the Taiwanese -- a clinic-based study. Cephalalgia 2004; 24:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/10\">",
"      Manzoni GC. Cluster headache and lifestyle: remarks on a population of 374 male patients. Cephalalgia 1999; 19:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/11\">",
"      Sjaastad O, Shen JM, Stovner LJ, Els&aring;s T. Cluster headache in identical twins. Headache 1993; 33:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/12\">",
"      Russell MB, Andersson PG, Thomsen LL. Familial occurrence of cluster headache. J Neurol Neurosurg Psychiatry 1995; 58:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/13\">",
"      El Amrani M, Ducros A, Boulan P, et al. Familial cluster headache: a series of 186 index patients. Headache 2002; 42:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/14\">",
"      Leone M, Russell MB, Rigamonti A, et al. Increased familial risk of cluster headache. Neurology 2001; 56:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/15\">",
"      Russell MB, Andersson PG, Thomsen LL, Iselius L. Cluster headache is an autosomal dominantly inherited disorder in some families: a complex segregation analysis. J Med Genet 1995; 32:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/16\">",
"      Lampl C. Childhood-onset cluster headache. Pediatr Neurol 2002; 27:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/17\">",
"      Evers S, Frese A, Majewski A, et al. Age of onset in cluster headache: the clinical spectrum (three case reports). Cephalalgia 2002; 22:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/18\">",
"      Rozen TD. Childhood exposure to second-hand tobacco smoke and the development of cluster headache. Headache 2005; 45:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/19\">",
"      Black DF, Swanson JW, Stang PE. Decreasing incidence of cluster headache: a population-based study in Olmsted County, Minnesota. Headache 2005; 45:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/20\">",
"      Manzoni GC, Terzano MG, Bono G, et al. Cluster headache--clinical findings in 180 patients. Cephalalgia 1983; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/21\">",
"      May A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 2005; 366:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/22\">",
"      Drummond PD. Dysfunction of the sympathetic nervous system in cluster headache. Cephalalgia 1988; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/23\">",
"      Drummond PD. Sweating and vascular responses in the face: normal regulation and dysfunction in migraine, cluster headache and harlequin syndrome. Clin Auton Res 1994; 4:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/24\">",
"      Drummond PD. Mechanisms of autonomic disturbance in the face during and between attacks of cluster headache. Cephalalgia 2006; 26:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/25\">",
"      Ekbom K. Evaluation of clinical criteria for cluster headache with special reference to the classification of the International Headache Society. Cephalalgia 1990; 10:195.",
"     </a>",
"    </li>",
"    <li>",
"     Sjaastad, O (Ed). Cluster Headache Syndrome. W B Saunders Company Ltd, London 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/27\">",
"      Sandrini G, Friberg L, J&auml;nig W, et al. Neurophysiological tests and neuroimaging procedures in non-acute headache: guidelines and recommendations. Eur J Neurol 2004; 11:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/28\">",
"      Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/29\">",
"      Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14327/abstract/30\">",
"      Favier I, van Vliet JA, Roon KI, et al. Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases. Arch Neurol 2007; 64:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3326 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14327=[""].join("\n");
var outline_f13_63_14327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autonomic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Circadian periodicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Paroxysmal hemicrania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUNCT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Secondary cluster headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/57/35733\" title=\"figure 1\">",
"      Pathogenesis cluster headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/58/13228\" title=\"table 1\">",
"      Diagnostic criteria cluster headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/12/42188\" title=\"table 2\">",
"      Clinical features trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/2/11308\" title=\"table 3\">",
"      Diagnostic criteria paroxysmal hemicrania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/4/14412\" title=\"table 4\">",
"      Diagnostic criteria SUNCT SUNA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=related_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=related_link\">",
"      Paroxysmal hemicrania: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_63_14328="Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults";
var content_f13_63_14328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Steven R Mess&eacute;, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Robert S Schwartz, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Joseph K Perloff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14328/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/63/14328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options for prevention of recurrent stroke in patients with an atrial septal abnormality, including patent foramen ovale (PFO), ostium secundum atrial septal defect (ASD), and atrial septal aneurysm (ASA), are medical therapy with antiplatelet agents or anticoagulants, and surgical or percutaneous closure of the defect. The choice depends upon several factors, especially upon the type of abnormality.",
"   </p>",
"   <p>",
"    Existing retrospective and prospective data are conflicting with regard to the relationship between ischemic stroke and PFO, ASA, and ASD. Population-based studies suggest that a PFO, even when large, is not an independent risk factor for cryptogenic ischemic stroke. The evidence regarding sources of cerebral emboli and the risk of stroke related to atrial septal abnormalities, as well as cryptogenic stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link\">",
"     \"Cryptogenic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the uncertainty about the causal association between atrial septal abnormalities and stroke, some of the therapeutic options discussed below may prove to be overly aggressive. In addition to medical management, review of this topic will include the surgical and percutaneous options currently available for the prevention of embolic stroke related to an atrial septal abnormality.",
"   </p>",
"   <p>",
"    The possible relationship of migraine with right-to-left cardiac shunt is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649662#H130649662\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Right-to-left cardiac shunt'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H27#H27\">",
"     \"Preventive treatment of migraine in adults\", section on 'Closure of right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY FOR SECONDARY STROKE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 ACCP guidelines recommend antiplatelet therapy for patients with cryptogenic ischemic stroke and a PFO and state that anticoagulation is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines state that antiplatelet therapy is reasonable for patients with an ischemic stroke or TIA and a PFO, and that oral anticoagulation is reasonable for high-risk patients who have other indications such as a hypercoagulable state [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Isolated PFO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of a patient with a patent foramen ovale (PFO) and a stroke or transient ischemic attack (TIA) who does not receive PFO treatment is unknown. The rationale for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy comes from clinical data and from evidence that the paradoxical particles associated with these transient ischemic events are small",
"    <span class=\"nowrap\">",
"     platelet/fibrin",
"    </span>",
"    aggregates that originate in the systemic venous bed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H16#H16\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Source of the embolus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is suggested by the French PFO-atrial septal aneurysm (ASA) study, which found that among the 216 patients with a cryptogenic stroke and an isolated PFO, the incidence of a recurrent stroke on aspirin was only 2.3 percent after four years, a value that was comparable to the 4.2 percent risk in patients with no atrial septal abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    also comes from the PICSS study, which did",
"    <strong>",
"     not",
"    </strong>",
"    demonstrate a statistical difference between the effects of aspirin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    on the risk of subsequent stroke or death among patients with cryptogenic stroke and a PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/4\">",
"     4",
"    </a>",
"    ]. However, PICSS was primarily designed as a prognostic study and was underpowered to demonstrate a treatment effect. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PFO with ASA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The French PFO-ASA study included 51 patients under the age of 55 with cryptogenic stroke who had both an atrial septal aneurysm (ASA) and a PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of recurrent stroke with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy at four years was 15.2 percent (hazard ratio 4.2 when compared with the absence of these abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/3\">",
"     3",
"    </a>",
"    ]. These findings suggest that more aggressive therapy such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or surgical repair may be the better option in such patients. However, there was no difference in outcome between aspirin and warfarin therapy among patients with both an ASA and a PFO in PICSS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Isolated ASA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 78 percent of atrial septal aneurysms (ASA) are associated with a right-to-left shunt. Given the rarity of an isolated ASA, the best treatment for those with associated cerebral embolism is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. The only major study that specifically evaluated patients with an isolated ASA and cryptogenic stroke was the French PFO-ASA study: 10 patients had an isolated ASA, none of whom had a recurrent stroke while on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/3\">",
"     3",
"    </a>",
"    ]. Treating such patients with aspirin makes physiologic sense, since the emboli probably originate from",
"    <span class=\"nowrap\">",
"     fibrin/platelet",
"    </span>",
"    material attached to the left atrial surface of the aneurysm, with dislodgement resulting from abrupt oscillations of the mobile aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLOSURE OF THE DEFECT FOR SECONDARY STROKE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closure of a patent foramen ovale (PFO) or atrial septal defect (ASD) can be achieved surgically or percutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of closure of a PFO or ASD on the rate of recurrent stroke has not been established. There are multiple mechanisms by which recurrent stroke can occur after PFO closure. In a minority of patients, a residual shunt persists, allowing continued paradoxical embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Alternatively, thrombus may spontaneously form on the left atrial wall of the PFO due to stagnant or turbulent blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, there is evidence to support an increased risk of atrial arrhythmias in patients with PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/15\">",
"     15",
"    </a>",
"    ]. Finally, given the high rate of PFO in the general population, it is possible that the atrial communication is an \"innocent bystander.\" This is particularly applicable to patients above age 55 and those with known risk factors for stroke (hypertension, hypercholesterolemia, smoking) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Causality can best be inferred in patients under age 55 with no other apparent etiology for stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of ongoing randomized trials have been designed to compare percutaneous closure against best medical therapy. Eligible patients should be encouraged to participate in these trials. Closure outside of a trial can be considered if the cerebral ischemic events are recurrent despite appropriate medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported efficacy of surgical closure of a PFO in patients with prior cerebrovascular ischemic events has been variable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/16,20-22\">",
"     16,20-22",
"    </a>",
"    ], and randomized trials comparing medical therapy have not been performed.",
"   </p>",
"   <p>",
"    Rates of recurrent cerebrovascular events following surgical closure have ranged from 7 to 14 percent at one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/16,20\">",
"     16,20",
"    </a>",
"    ]. These events are likely due to mechanisms unrelated to paradoxical embolization, as illustrated by a report of 91 patients (mean age 44 years) with one or more cerebrovascular ischemic events who underwent surgical PFO closure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/20\">",
"     20",
"    </a>",
"    ]. The overall freedom from an ischemic episode at one and four years was 93 and 83 percent, respectively. The recurrent events were TIAs (there were no cerebral infarctions), one of which was attributed to giant cell arteritis. Transesophageal echocardiography showed that the closures were intact in all patients, implying that paradoxical embolization was not the cause of the ischemic events.",
"   </p>",
"   <p>",
"    Older age may be an important risk factor for recurrence, as suggested by the results of a study involving 28 patients with a cryptogenic stroke who underwent surgical closure of a PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/16\">",
"     16",
"    </a>",
"    ]. There were four recurrent neurologic events at a mean follow-up of 19 months, all in the 11 patients who were &ge;45 years of age. Since older patients are more likely to have stroke risk factors other than PFO, this observation is compatible with the suggestion in the previous study that factors other than paradoxical embolization may cause recurrent neurologic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Percutaneous closure of PFO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of percutaneous PFO closure compared with surgical closure or medical management for preventing recurrent embolic events is not established.",
"   </p>",
"   <p>",
"    The best available evidence comes from the CLOSURE I trial and indicates that device closure of a PFO does",
"    <strong>",
"     not",
"    </strong>",
"    offer significant benefit over medical therapy alone for the prevention of recurrent stroke or TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/23\">",
"     23",
"    </a>",
"    ]. In CLOSURE I, adult patients &le;60 years old with a PFO and cryptogenic stroke or TIA were randomly assigned either to PFO device closure (n=447) or to medical therapy (n=462). Patients in the device group were treated with the STARFlex PFO closure device and received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for six months followed by aspirin alone; those in the medical therapy group were treated with aspirin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or both. The primary endpoint was a composite of stroke or TIA at two years plus 30-day mortality and neurologic mortality beyond 30 days. At two years by intention-to-treat analysis, there was no significant difference between device closure and medical therapy in the rates of the primary endpoint (5.5 versus 6.8 percent), stroke (2.9 versus 3.1 percent), or TIA (3.1 versus 4.1 percent). There was no benefit for device closure in subgroups, including those stratified by degree of right to left shunt, or by the presence or absence of atrial septal aneurysm. Major vascular complications were significantly more frequent with device closure (3.2 versus 0 percent), as was atrial fibrillation (5.7 versus 0.7 percent), most of which was periprocedural. The device placement procedural success rate was approximately 90 percent, suggesting that device failure was not responsible for lack of benefit.",
"   </p>",
"   <p>",
"    Objections raised to the negative CLOSURE I trial results include the finding that 5 of the 12 stroke outcomes in the device arm were associated with either device thrombosis (n = 2) or atrial fibrillation that was probably induced by the device (n = 3), leaving open the possibility that another device could do better. In addition, several factors may have limited the ability of the trial to detect a treatment effect. One is that almost 30 percent of patients in both arms of the trial had TIA with no evidence of infarction on diffusion-weighted imaging at baseline, and accumulating data suggest that this population is probably at very low risk of stroke (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\", section on 'ABCD2 score'",
"    </a>",
"    ) regardless of PFO closure. Another is that three-quarters or more of recurrent TIA or stroke in both arms of the trial were possibly due to a cause unrelated to paradoxical embolism, including lacunar infarction, cardiogenic embolism from atrial fibrillation, and even vasculitis, suggesting that the index ischemic events in some patients were not truly cryptogenic, in which case there would be no expected benefit from PFO closure.",
"   </p>",
"   <p>",
"    Additional skepticism regarding the validity of the CLOSURE I trial results include concerns that it was underpowered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/24\">",
"     24",
"    </a>",
"    ], that two-year follow-up was not long enough to demonstrate benefit (eg, the trials of endarterectomy for asymptomatic carotid disease would not have demonstrated benefit at only two years), and suspicion that patients at high-risk of recurrent embolism were disproportionately treated outside of the trial with PFO closure. Thus, given the potential limitations of the CLOSURE I trial, it is possible that further randomized trials of alternative PFO closure devices may demonstrate benefit of device closure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Earlier nonrandomized comparisons suggested that PFO closure was a viable therapeutic option. A systematic review published in 2012 included 57 longitudinal studies that investigated percutaneous PFO closure or medical treatment in 8916 patients with paradoxical embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/26\">",
"     26",
"    </a>",
"    ]. Most of the included studies were single-arm reports of PFO closure. The summary incidence rate (IR) of recurrent stroke with PFO closure was 0.36 per 100 person-years (95% CI 0.24&ndash;0.56), while the IR with medical therapy (antiplatelets or anticoagulation) was 2.53 per 100 person-years (95% CI 1.91&ndash;3.35). In the seven comparative observational studies, the rate of recurrent stroke was significantly lower with PFO closure compared with medical therapy (IR ratio 0.19, 95% CI 0.07&ndash;0.54).",
"    <br/>",
"    <br/>",
"    These results from the nonrandomized studies in the systematic review are strikingly different from those calculated for the CLOSURE I trial, where the IRs of recurrent stroke for PFO closure and medical treatment were 1.34 and 1.41 per 100 person-years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, the IR of recurrent stroke for patients randomized to device closure in the CLOSURE I trial was nearly four-fold higher than the rate for patients treated with device closure in the observational studies, while the IR of recurrent stroke for patients randomized to medical treatment in CLOSURE I was lower than the rate for patients receiving medical treatment in the observational reports. Inherent limitations of observational studies (eg, selection bias, measurement bias, publication bias) may account for some or all of these discrepancies.",
"   </p>",
"   <p>",
"    In summary, nonrandomized observational studies have suggested benefit of PFO closure for preventing recurrent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/26\">",
"     26",
"    </a>",
"    ], whereas the best available evidence &ndash; the randomized controlled CLOSURE I trial &ndash; showed no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/23\">",
"     23",
"    </a>",
"    ]. The inherent limitations of observational data and concerns regarding the validity of the CLOSURE I trial results preclude definitive conclusions. Therefore, additional randomized trial data are required to determine whether device PFO closure improves outcomes compared to medical therapy, and eligible patients and clinicians who care for them are strongly encouraged to enroll in ongoing randomized trials to determine the effectiveness of this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of PFO closure devices are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=see_link\">",
"     \"Devices for percutaneous closure of a secundum atrial septal defect\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percutaneous closure of PFO with ASA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Percutaneous closure of PFO'",
"    </a>",
"    above), results from the only completed randomized controlled trial found no benefit of device closure of PFO regardless of the presence of an atrial septal aneurysm (ASA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/23\">",
"     23",
"    </a>",
"    ]. A nonrandomized study addressing the safety and efficacy of percutaneous closure of a PFO with an ASA evaluated 141 consecutive patients with &ge;1 paradoxical embolic event; the results were compared with those in 220 patients with a PFO alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/12\">",
"     12",
"    </a>",
"    ]. The two groups had equivalent rates of device success (99.3 and 99.5 percent), procedural complications (0.7 and 3.2 percent), abolition of right-to left shunting (86 and 85 percent), and freedom from recurrent TIA, stroke, or peripheral embolism at four years (95 and 94 percent). The only predictor of recurrence in patients with PFO and ASA was a residual right-to-left shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Percutaneous closure of ASD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is somewhat less controversy regarding management of patients with an atrial septal defect (ASD). Depending on the volume of left-to-right shunt, there is a possibility of right ventricular failure. Thus, many have argued that patients with probable paradoxical embolism and ASD should have the shunt closed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of atrial septal defects in adults\", section on 'Indications for defect closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of stroke associated with patent foramen ovale (PFO), atrial septal defect (ASD)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrial septal aneurysm (ASA) in asymptomatic individuals is uncertain, and the role of preventative treatment has not been established. However, the available evidence from population-based studies suggests that PFO and large PFO are not independent risk factors for ischemic stroke in otherwise asymptomatic individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H13#H13\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Population-based studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines suggest not using antithrombotic therapy for patients with asymptomatic PFO or ASA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/28\">",
"     28",
"    </a>",
"    ]. The 2004 American Academy of Neurology (AAN) practice parameter concluded that the risk of primary stroke is low in individuals with PFO, suggesting that primary prevention measures are unlikely to have a worthwhile risk-to-benefit ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with high cardiovascular risk and an incidentally discovered PFO, surgical closure may actually increase the risk of postoperative stroke. This conclusion comes from a retrospective study of 13,092 adults (mean age 63) without a prior diagnosis of PFO or ASD who had cardiothoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/29\">",
"     29",
"    </a>",
"    ]. A PFO was detected intraoperatively in 2277 patients, and closure was performed at the discretion of the surgeon in 639 patients (28 percent). Using propensity-matched analysis, the risk of perioperative stroke was significantly higher in patients who had surgical PFO closure than in those who did not (2.8 versus 1.2 percent; odds ratio 2.47, 95% CI 1.02-6.0). There was no difference between the two groups in long-term survival. The uncontrolled retrospective design and small number of events limit the strength of this study.",
"   </p>",
"   <p>",
"    Given the lack of evidence to support therapy, we suggest no specific treatment of incidentally discovered PFO, ASD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASA in asymptomatic patients. Nevertheless, other modifiable cardiovascular risk factors should be treated appropriately to reduce the risk of stroke and cardiovascular disease. These risk reduction strategies are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=see_link\">",
"       \"Patient information: Patent foramen ovale (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for patients with a patent foramen ovale (PFO) or secundum atrial septal defect (ASD) who have had a cryptogenic ischemic stroke or TIA is not established. Although it seems intuitive that closure of the defect would provide optimal protection, the best available evidence suggests that PFO closure is no better than medical therapy, at least in part because the procedure has a small but real associated risk and because most recurrent cerebral events are unrelated to paradoxical embolization. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Closure of the defect for secondary stroke prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of PFO, with or without an ASA, is of uncertain importance for the development of a first or recurrent cryptogenic stroke. This issue is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H8#H8\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Risk of embolic stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 ACCP guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    over no aspirin for patients with cryptogenic stroke and PFO or atrial septal aneurysm (ASA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/28\">",
"     28",
"    </a>",
"    ]. For patients who experience recurrent events despite aspirin therapy, the ACCP guidelines suggest treatment with vitamin K antagonist therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) and consideration of device closure over aspirin. For patients with cryptogenic stroke and PFO who have evidence of DVT, the ACCP guidelines recommend vitamin K antagonist therapy for three months and consideration of device closure over no vitamin K antagonist therapy or aspirin therapy.",
"   </p>",
"   <p>",
"    Given the uncertainty about the causal association between atrial septal abnormalities and stroke and the low risk of recurrence, some of the available therapeutic options may prove to be overly aggressive. Nonetheless, most patients with an ischemic stroke or TIA should be treated with all available risk reduction strategies, notwithstanding the presence or absence of traditional thresholds for defining hypertension and hyperlipidemia. Currently viable strategies include blood pressure reduction, statins, and antiplatelet therapy. Thus, at a minimum, antiplatelet therapy, statins, and antihypertensive agents are appropriate for secondary stroke prevention in patients with atrial septal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations for secondary stroke prevention are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All eligible patients with cryptogenic stroke and PFO should be encouraged to participate in one of the remaining ongoing trials comparing closure with medical therapy.",
"     </li>",
"     <li>",
"      In lieu of clinical trial participation, we suggest antiplatelet therapy for patients with cryptogenic ischemic stroke and a PFO, with or without an ASA, rather than percutaneous PFO closure or anticoagulant therapy. For patients who experience recurrent cryptogenic TIA or stroke despite antiplatelet therapy, we suggest anticoagulant therapy or percutaneous PFO closure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy for secondary stroke prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend antiplatelet therapy for patients with cryptogenic ischemic stroke and an isolated ASA. For patients with an ASA and recurrent stroke on antiplatelet therapy, we suggest anticoagulant therapy if a follow-up investigation for other causes of stroke is unrevealing. In rare instances, surgical excision of the ASA may be considered if antiplatelet therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy fails to prevent recurrence of an embolic stroke or TIA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14328/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Isolated ASA'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a cryptogenic stroke and atrial septal abnormality (PFO, ASA, or ASD) who have evidence of acute venous thromboembolism, anticoagulation is generally used for several months specifically to treat for venous thromboembolism. Antiplatelet therapy for secondary stroke prevention should be started when anticoagulation is discontinued. However, patients with an idiopathic deep vein thrombosis appear to be at appreciable risk for recurrence and may benefit from long-term anticoagulation. The treatment of venous thromboembolism is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"       \"Treatment of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      therapy is reasonable for high-risk patients who have other indications for oral anticoagulation such as a hypercoagulable state. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical therapy for secondary stroke prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain general measures may be beneficial independent of therapy for the PFO or ASD. In particular, embolic material may originate in lower extremity veins. Accordingly, patients at risk should avoid sitting with knees flexed and legs dependent, crossing the legs when sitting, and prolonged passive standing. Risk is implicit during long airplane flights; passengers should be encouraged to ambulate regularly and avoid dehydration. These factors are particularly important in patients in whom deep vein thrombosis was identified at the time of the initial cerebrovascular event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H16#H16\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Source of the embolus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of stroke associated with an incidentally discovered PFO, ASD,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASA in asymptomatic individuals is uncertain. In addition, the role of preventative treatment in this setting has not been established. Therefore, for asymptomatic patients with PFO, ASD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ASA, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    treating the atrial septal abnormality itself. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Asymptomatic patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other modifiable cardiovascular risk factors should be treated appropriately. Risk reduction strategies for primary prevention of cardiovascular disease are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/1\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/2\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/3\">",
"      Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/4\">",
"      Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/5\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/6\">",
"      M&uuml;gge A, Daniel WG, Angermann C, et al. Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation 1995; 91:2785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/7\">",
"      Mess&eacute; SR, Silverman IE, Kizer JR, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/8\">",
"      Pearson AC, Nagelhout D, Castello R, et al. Atrial septal aneurysm and stroke: a transesophageal echocardiographic study. J Am Coll Cardiol 1991; 18:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/9\">",
"      Nedeltchev K, Arnold M, Wahl A, et al. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry 2002; 72:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/10\">",
"      Windecker S, Wahl A, Chatterjee T, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/11\">",
"      Mart&iacute;n F, S&aacute;nchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002; 106:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/12\">",
"      Wahl A, Krumsdorf U, Meier B, et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/13\">",
"      Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really \"shut the door?\" A prospective study with transcranial Doppler. Stroke 2004; 35:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/14\">",
"      Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993; 24:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/15\">",
"      Berthet K, Lavergne T, Cohen A, et al. Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause. Stroke 2000; 31:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/16\">",
"      Homma S, Di Tullio MR, Sacco RL, et al. Surgical closure of patent foramen ovale in cryptogenic stroke patients. Stroke 1997; 28:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/17\">",
"      Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/18\">",
"      Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/19\">",
"      Holmes DR Jr, Cabalka A. Was your mother right--do we always need to close the door? Circulation 2002; 106:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/20\">",
"      Dearani JA, Ugurlu BS, Danielson GK, et al. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 1999; 100:II171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/21\">",
"      Devuyst G, Bogousslavsky J, Ruchat P, et al. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996; 47:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/22\">",
"      Ruchat P, Bogousslavsky J, Hurni M, et al. Systematic surgical closure of patent foramen ovale in selected patients with cerebrovascular events due to paradoxical embolism. Early results of a preliminary study. Eur J Cardiothorac Surg 1997; 11:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/23\">",
"      Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/24\">",
"      Johnston SC. Patent foramen ovale closure--closing the door except for trials. N Engl J Med 2012; 366:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/25\">",
"      Thaler DE, Wahl A. Critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: the hole truth? Stroke 2012; 43:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/26\">",
"      Kitsios GD, Dahabreh IJ, Abu Dabrh AM, et al. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012; 43:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/27\">",
"      O'Gara PT, Messe SR, Tuzcu EM, et al. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation 2009; 119:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/28\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14328/abstract/29\">",
"      Krasuski RA, Hart SA, Allen D, et al. Prevalence and repair of intraoperatively diagnosed patent foramen ovale and association with perioperative outcomes and long-term survival. JAMA 2009; 302:290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1100 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14328=[""].join("\n");
var outline_f13_63_14328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL THERAPY FOR SECONDARY STROKE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Isolated PFO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PFO with ASA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Isolated ASA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLOSURE OF THE DEFECT FOR SECONDARY STROKE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Percutaneous closure of PFO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percutaneous closure of PFO with ASA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Percutaneous closure of ASD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/62/36837?source=related_link\">",
"      Devices for percutaneous closure of a secundum atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/1/12306?source=related_link\">",
"      Patient information: Patent foramen ovale (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_63_14329="Management of Turner syndrome (gonadal dysgenesis)";
var content_f13_63_14329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Turner syndrome (gonadal dysgenesis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Paul Saenger, MD, MACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14329/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14329/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/63/14329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner syndrome (gonadal dysgenesis) is an important cause of short stature in girls and primary amenorrhea in young women that is usually caused by loss of part or all of an X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the treatment of patients with this disorder. Therapy varies with the age of the patient and is directed at the congenital anomalies and symptoms related to the anomalies and those of estrogen deficiency (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"UTD.htm?11/20/11598\">",
"     table 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical manifestations and diagnosis of Turner syndrome are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information for caregivers and patients can be obtained from:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Turner Syndrome Society of the United States",
"    <br/>",
"    &nbsp; &nbsp;Tel: 1-800-365-9944",
"    <br/>",
"    &nbsp;&nbsp;&nbsp;&nbsp;",
"    <a class=\"external\" href=\"file://www.turnersyndrome.org/\">",
"     www.turnersyndrome.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRENATAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of Turner syndrome are sometimes discovered incidentally during chorionic-villus sampling or amniocentesis performed for unrelated reasons, such as advanced maternal age or congenital anomalies. Ultrasonography may show increased nuchal translucency, which is a good marker for fetal chromosomal defects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/3\">",
"     3",
"    </a>",
"    ]. No intervention is indicated at this time. The parents should receive counseling, as they may elect to terminate the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H26#H26\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Turner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] suggest that girls with incidentally diagnosed Turner syndrome, particularly those with",
"    <span class=\"nowrap\">",
"     45,X/46,XX",
"    </span>",
"    mosaicism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/5\">",
"     5",
"    </a>",
"    ], have a milder phenotype than those diagnosed on the basis of clinical suspicion. Prospective studies confirming these results are necessary before this information can be used in prenatal counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFANTS AND CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular anomalies in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, all infants and children with Turner syndrome should be studied by echocardiography or magnetic resonance imaging to detect cardiovascular anomalies such as coarctation of the aorta or a bicuspid aortic valve, both of which are most common causes of morbidity and mortality in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a comprehensive exam, including blood pressure in all extremities, should be performed (",
"    <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"UTD.htm?21/44/22222\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An approach to screening for cardiovascular anomalies recommended by a consensus group is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"UTD.htm?21/44/22222\">",
"     algorithm 1",
"    </a>",
"    ). In a series of 179 women with Turner syndrome who underwent clinical examination and echocardiography, 26 percent had a cardiovascular malformation, 10 percent had a coarctation, and 18 percent had aortic valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those found to have coarctation of the aorta should undergo surgical correction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Those with other anomalies should be followed regularly. Girls who have only had echocardiography should undergo MRI when they are old enough to tolerate the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition to routine monitoring of blood pressure, repeat imaging is suggested about every 5 to 10 years, at the time of transition from pediatric to adult care, before attempting pregnancy, or with the appearance of hypertension (",
"      <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"UTD.htm?21/44/22222\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adults'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007 American Heart Association guidelines on the prevention of bacterial endocarditis recommended that only patients with the highest risk of the development of endocarditis receive antimicrobial prophylaxis. Most patients with valvular heart disease, including Turner syndrome patients with bicuspid aortic valve, are not included in this group and therefore no longer require antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short stature combined with a square appearance is the most common clinical feature of Turner syndrome. The adult height of untreated patients correlates significantly with mid-parental height (ie, the height corresponds to the average of the height percentiles of the mother and the father).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    therapy is recommended to maximize final height. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    , an anabolic steroid, to growth hormone therapy appears to improve results, as described in the following section. (See",
"    <a class=\"local\" href=\"#H7637360\">",
"     'Growth hormone with oxandrolone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Growth hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    therapy should be initiated as soon as the height of a girl with Turner syndrome falls below the fifth percentile for age, which usually occurs between two and five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ]. Growth hormone should initially be given subcutaneously in a dose of 0.375",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week (0.053",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for initiating therapy with human growth hormone as soon as height falls below the fifth percentile for age is the possible attainment of normal adult height. This was illustrated in a trial of 68 younger girls (mean age between six and seven years) with Turner syndrome who were randomly assigned to three different regimens of growth hormone (",
"    <a class=\"graphic graphic_figure graphicRef60029 \" href=\"UTD.htm?19/36/20046\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/10\">",
"     10",
"    </a>",
"    ]. The girls attained normal adult height (mean values 159 to 162 cm). Escalating doses over time above the initial 0.045",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day resulted in a 2 to 3 cm greater increment in growth, although the safety of this approach is not known. These excellent height results were achieved after an average treatment duration of seven years. Similar results were reported from an observational registry of 344 patients with Turner syndrome treated with growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of growth hormone treatment is further supported by a placebo-controlled trial in which treatment and observation were continued until adult height was achieved. In this study, girls 5 to 12.5 years of age were treated with growth hormone, 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight three times a week, with or without low dose estradiol orally or with corresponding placebos. The group treated with growth hormone alone achieved a mean adult height of 148 cm, which was 0.78 SD score (approximately 5 cm) greater than those treated with double-placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/12\">",
"     12",
"    </a>",
"    ]. The group treated with estradiol as well as growth hormone gained an additional 2 cm. The height increment attributable to growth hormone therapy was less than in newer studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], perhaps because treatment was started at a later age and the dose of growth hormone was somewhat lower than is currently used.",
"   </p>",
"   <p>",
"    Together, the findings from these studies demonstrate that early initiation of growth hormone therapy is important to achieve clinically significant increments in height, and that higher doses (eg, above 0.045",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) yield additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/13\">",
"     13",
"    </a>",
"    ]. We do not recommend the use of low-dose estrogen during the prepubertal period because it appears to have little effect on adult height and has not been adequately studied to assess possible adverse effects.",
"   </p>",
"   <p>",
"    In addition to its effect on longitudinal bone growth, growth hormone therapy may have an impact on body composition. In a cross sectional-study of girls with Turner syndrome, growth hormone therapy increased lean body mass and decreased body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/14\">",
"     14",
"    </a>",
"    ]. These changes were independent of estrogen exposure. Growth hormone therapy does not appear to have a deleterious effect on blood pressure, left ventricular function, or aortic diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Adverse effects of growth hormone therapy, including intracranial hypertension, slipped capital femoral epiphyses, and pancreatitis, are similar to those seen in other children receiving the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7637360\">",
"    <span class=\"h3\">",
"     Growth hormone with oxandrolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In girls 9 to 12 years of age with extreme short stature, adding an androgen (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    at a dose of 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or less) to growth hormone therapy should be considered. Higher doses of oxandrolone may result in virilization and may accelerate skeletal maturation. Therapy should be continued until little growth potential remains (eg, bone age exceeds 15 years and growth slows to less than 2 cm per year).",
"   </p>",
"   <p>",
"    The efficacy of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    to growth hormone therapy during puberty was illustrated by a trial in which 106 girls with Turner syndrome were randomized to receive either oxandrolone (0.05",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    maximum 2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo beginning at nine years of age, in addition to standard growth hormone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/18\">",
"     18",
"    </a>",
"    ]. Those with evidence of ovarian failure at 12 years of age were further randomized to ethinyl estradiol to induce puberty at 12 years versus 14 years (the latter group, the &ldquo;delayed pubertal induction&rdquo; group, received placebo from age 12 to 14 years). Both oxandrolone and late pubertal induction increased final height: oxandrolone by an average of 4.6 cm (95% CI 1.9-7.2 cm), and delayed pubertal induction by an average of 3.8 cm (95% CI 0-7.5 cm). In those who completed both randomizations, the improvement in final height with oxandrolone, delayed pubertal induction, or both was similar (approximately 7 cm). Thus, both interventions had a beneficial effect on final height, but they were not additive. Based upon these findings, we suggest that either oxandrolone therapy or delayed pubertal induction (but not both) be offered in addition to growth hormone therapy for girls with extreme short stature at nine years of age. Growth hormone and oxandrolone had similar beneficial effects in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Early addition of estrogen appears to decelerate height velocity and reduce the gain in height [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls with Turner syndrome have an increased incidence of renal anomalies; hypertension, even in the absence of cardiac or renal anomalies; hypothyroidism caused by chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/23\">",
"     23",
"    </a>",
"    ]; celiac disease; otitis media due to developmental distortion of the eustachian tube; strabismus, amblyopia, and ptosis; and scoliosis, which becomes most apparent during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Problems related to these anomalies should be sought during regular follow-up examinations (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"UTD.htm?11/20/11598\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7,24\">",
"     7,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all girls with Turner syndrome need exogenous estrogen to do the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induce and maintain sexual development and cyclic uterine bleeding (with a progestin).",
"     </li>",
"     <li>",
"      Complete adolescent bone maturation, and to optimize peak bone mass [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Optimize cognitive and motor function (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Cognitive function and learning disabilities'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing and dosing of estrogen therapy should be selected to reflect normal puberty. Beginning treatment with low-dose estradiol around age 12 years of age permit a normal timing and pace of puberty without compromising adult height. Replacement is usually begun at doses between one-tenth and one-eighth of the adult replacement dose, and then increased gradually during the next two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth hormone and estrogen are given together until epiphyseal fusion occurs, then growth hormone is stopped.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     Oxandrolone",
"    </a>",
"    should be discontinued when estrogen treatment is started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of estrogen should be low, eg, a transdermal estradiol patch at 6.25 micrograms daily, depot estradiol at 0.2 to 0.4 mg monthly, or micronized estradiol at 0.25 mg daily by mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose should be increased gradually during the following two years to an adult dose (",
"    <a class=\"graphic graphic_table graphicRef62742 \" href=\"UTD.htm?27/55/28540\">",
"     table 2",
"    </a>",
"    ). Typical adult doses are transdermal estradiol patch 100 to 200 micrograms daily, 2 to 4 mg micronized estradiol daily by mouth, 20 micrograms ethinyl estradiol daily by mouth, or 1.25 to 2.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    daily by mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for the gradual increase in estrogen dose is to mimic normal puberty and breast development. Although there are no available clinical data, many clinicians feel that this approach results in more normal breast development than when high doses are initiated. However, some girls do not think that their breast development is optimal even after appropriate estrogen therapy. This is hard to prove, but could be due to poor development of breast anlage, widely spaced nipples, and the shield chest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls receiving estrogen must be given cyclic progestin therapy to prevent endometrial hyperplasia due to unopposed estrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .) It is usually given as micronized progesterone at a dose of 200 mg daily for 10 days each month. Progestin therapy should be begun after two years of estrogen therapy, or when vaginal breakthrough bleeding first occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ]. Alternatively, estrogen can be given for one to two years, and the woman then switched to a low-estrogen oral contraceptive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Edema and keloid formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema in Turner syndrome is usually due to lymphatic obstruction. It can be controlled in most cases with support stockings; vascular surgery aimed at the correction of the lymphedema is rarely indicated.",
"   </p>",
"   <p>",
"    Girls with Turner syndrome have a propensity to keloid formation. As a result, surgery should be avoided whenever possible.",
"   </p>",
"   <p>",
"    Additional recommendations have been published by the Turner Syndrome Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cognitive function and learning disabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Turner syndrome may have attention-deficit disorder and difficulties with visual-spatial organization, social cognition, and nonverbal problem-solving tasks such as mathematics. These issues should be addressed by early identification and implementation of specific educational strategies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Psychologic and educational issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that gonadal hormone replacement may have beneficial effects on cognitive function and learning disabilities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen replacement appears to have some benefits on cognitive function in pre-adolescent girls, but its effects in older individuals are unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/27\">",
"       27",
"      </a>",
"      ]. In a study of girls age seven to nine with Turner syndrome, low doses of ethinyl estradiol (25",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per day) improved verbal and nonverbal memory when compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/28\">",
"       28",
"      </a>",
"      ]. No effect on other verbal abilities or attention was seen. A similar report in slightly older girls suggested that estrogen replacement improved nonverbal processing speed and motor function [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, estrogen replacement did not improve the cognitive deficits in a series of 71 adult women with Turner syndrome whose cognitive phenotype was the same as that seen in childhood and adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Androgen replacement might also have an effect on cognitive function in girls with Turner syndrome. In a trial of 64 girls randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"       oxandrolone",
"      </a>",
"      (0.06",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      or placebo for two years, improvements were seen in working memory, but not in verbal abilities, spatial cognition, or executive function [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/31\">",
"       31",
"      </a>",
"      ]. Forty-four of the girls remained in the trial for an additional two years, and the group treated with oxandrolone had a lower frequency of severe arithmetic learning disability [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/32\">",
"       32",
"      </a>",
"      ]. Androgen replacement is typically used in combination with growth hormone to enhance growth in girls with extreme short stature. Because of potential side effects it is not used as standard therapy. (See",
"      <a class=\"local\" href=\"#H7637360\">",
"       'Growth hormone with oxandrolone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although gonadal hormone replacement is primarily used to promote sexual development, bone density, and growth, there may be additional benefits on cognitive function. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Estrogen therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very few girls with Turner syndrome go on to receive optimal care and surveillance as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/33\">",
"     33",
"    </a>",
"    ]. Women with Turner syndrome should be seen on a yearly basis for physical examination and biochemical testing for thyroid disease, glucose intolerance, dyslipidemia, and liver abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, screening for hearing loss and cardiovascular anomalies should be done at regular intervals (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"UTD.htm?11/20/11598\">",
"     table 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"UTD.htm?21/44/22222\">",
"     algorithm 1",
"    </a>",
"    ). Detailed recommendations have been published by the Turner Syndrome Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiovascular anomalies in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with Turner syndrome are at increased risk for cardiovascular morbidity and mortality, and should undergo regular cardiac examinations and imaging studies (both echocardiography and cardiac magnetic resonance imaging) to detect aortic root dilatation, valve disease, or other cardiovascular anomalies (",
"    <a class=\"graphic graphic_algorithm graphicRef69744 \" href=\"UTD.htm?21/44/22222\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7,35-37\">",
"     7,35-37",
"    </a>",
"    ]. Treatment with growth hormone does not appear to alter the size of the aorta or heart [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/16,38\">",
"     16,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to routine monitoring of blood pressure, repeat imaging is suggested about every 5 to 10 years, before attempting pregnancy, or with the appearance of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7,37\">",
"     7,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with Turner syndrome are also at risk for aortic dissection. To minimize this risk, close cardiovascular monitoring is required in patients with a dilated ascending aorta (aortic size index &gt;2.0",
"    <span class=\"nowrap\">",
"     cm/m).",
"    </span>",
"    Evidence-based recommendations for managing these patients are not available, but we suggest that measures used in patients with Marfan syndrome, such as beta-blockers, exercise restriction, and aggressive blood pressure control may be appropriate in this setting as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early and consistent estrogen replacement is recommended since it improves the lipid profile and decreases aortic stiffness.",
"   </p>",
"   <p>",
"    As noted above, the American Heart Association now recommends that only patients with the highest risk for endocarditis receive antimicrobial prophylaxis. Turner syndrome patients with bicuspid aortic valve would not be included in this group and therefore no longer require antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensorineural hearing impairment, predominantly at a frequency of 1000 to 2000 Hz (sensorineural dip), has been noted in more than 50 percent of adult Turner syndrome patients. The hearing loss is thought to be related to a defect in the outer hair cells of the lower middle coil of the cochlea. It is more common in women who have a 45,X or",
"    <span class=\"nowrap\">",
"     45,X/46,i(Xq)",
"    </span>",
"    karyotype and is known to deteriorate with age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This sensorineural hearing loss may be superimposed on conductive loss due to frequent otitis media in childhood. Thus, regular evaluation of hearing (every two to three years) is essential to the health care of women with Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Treatment of the hearing loss with hearing aids may prevent social hearing problems and isolation for these women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome involving hypertension, dyslipidemia, type 2 diabetes mellitus, and obesity is more common among adults with Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/42\">",
"     42",
"    </a>",
"    ]. Compared with normal population, the risk of type 2 diabetes mellitus in patients with Turner syndrome is increased by a factor of 4.4.",
"   </p>",
"   <p>",
"    Annual tests of fasting blood sugar and lipids are recommended; guidance on nutrition and physical activity should be part of the health care program (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"UTD.htm?11/20/11598\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of hypothyroidism in adults with Turner syndrome is 25 to 30 percent; up to 50 percent have thyroid antibodies, particularly women with isochromosome Xp. Yearly evaluation of thyroid function is recommended (",
"    <a class=\"graphic graphic_table graphicRef50455 graphicRef63261 graphicRef73981 \" href=\"UTD.htm?11/20/11598\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of celiac disease is increased in Turner syndrome, with approximately 4 to 6 percent of patients affected. Periodic screening with tissue transglutaminase IgA antibodies should begin in childhood, and should be repeated every two to five years in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Metabolic issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Abnormal liver enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raised liver enzymes, cirrhosis, and inflammatory bowel disease occur with a higher frequency in adult women with Turner syndrome. Problems related to these anomalies should be sought during regular follow-up examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/24,35,36\">",
"     24,35,36",
"    </a>",
"    ]. Yearly testing of liver enzymes is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with Turner syndrome are infertile, but in one retrospective study of 522 patients, three (without mosaicism) became pregnant without medical assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with Turner syndrome can carry a pregnancy after in vitro fertilization (IVF) using donor oocytes. The endometrial response of these patients to adequate estrogen and progestin treatment appeared to be normal in one [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/44\">",
"     44",
"    </a>",
"    ], but not another study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/45\">",
"     45",
"    </a>",
"    ]. However, pregnancy rates with this technology are similar to other women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of greater concern is a possible increase in mortality due to aortic dissection or rupture that has been reported in women with Turner syndrome achieving pregnancy through IVF with oocyte donation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/48\">",
"     48",
"    </a>",
"    ]. Therefore, before attempting to become pregnant, women with Turner syndrome should undergo a complete medical evaluation, with particular attention paid to cardiovascular and renal function, as recommended by the American Society of Reproductive Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/43,49\">",
"     43,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryopreservation of ovarian tissue from adolescent girls with Turner syndrome is currently under investigation. In one report, girls with the lowest serum FSH concentrations had the highest follicle density on ovarian biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Turner syndrome require estrogen and progestin replacement therapy until the expected age of menopause, ie, about age 50 (",
"    <a class=\"graphic graphic_table graphicRef62742 \" href=\"UTD.htm?27/55/28540\">",
"     table 2",
"    </a>",
"    ). The dose of estrogen should be sufficient to prevent the clinical manifestations and long-term sequelae of estrogen deficiency, in particular, bone loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Duration of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with premature ovarian failure are concerned about the potential cardiovascular and breast cancer risks of long-term estrogen therapy that has been reported in older postmenopausal women. However, the baseline risks of adverse events are much lower in these young women when compared with older, postmenopausal women. Most experts agree that women with premature ovarian failure should replace the hormones the ovary would normally provide them with until age 50 years, the average age of menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Breast cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;No large series of long-term hormone therapy and breast cancer risk are available for women with Turner syndrome. However, in a report of 62 patients with Turner syndrome who had been on hormone therapy for 20 to 40 years, no cases of breast cancer were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=see_link\">",
"     \"Management of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hepatic function",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been concern that treatment with estrogen might worsen hepatic function in patients with elevated liver enzymes. However, in a study of 80 women (ages 17 to 49) with Turner syndrome (44 percent of whom had elevated liver enzymes), hormone therapy (estrogen plus progestin) improved liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Turner syndrome who have received estrogen therapy usually have normal trabecular (spine) bone mineral density (BMD), when the measurement is adjusted for size (small size leads to underestimation of BMD with dual energy x-ray absorptiometry [DXA]). However, there may be an estrogen-independent defect in cortical bone in these patients. A baseline DXA should be done at the first visit with the adult provider. If BMD is normal, additional follow-up is done when the patient stops estrogen. If abnormal, further evaluation and treatment is the same as for other patients with low bone density or osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Osteoporosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall mortality rates in patients with Turner syndrome are increased approximately threefold when compared with the general population, with excess risk occurring at all ages, and for most major causes of death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This was best illustrated in a population-based study of 3439 patients with Turner syndrome in which the following results were seen (",
"    <a class=\"graphic graphic_figure graphicRef53850 \" href=\"UTD.htm?34/13/35024\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14329/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were a total of 296 deaths, significantly higher than expected when compared with national mortality rates (standardized mortality rate [SMR] = 3.0). The relative risk of death was increased at all ages, but the absolute excess risk of death was higher in older patients.",
"     </li>",
"     <li>",
"      Noncongenital cardiovascular disease, most commonly coronary heart disease and stroke in older patients, accounted for 41 percent of deaths. Estrogen deficiency throughout life may play a role in this complication.",
"     </li>",
"     <li>",
"      Congenital cardiovascular anomalies accounted for 8 percent of deaths. Aortic aneurysm was associated with the greatest increase in cardiovascular mortality rates, occurring in 17 women ages 15 to 44 years, seven of whom were under age 30 years (SMR = 280). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cardiovascular anomalies in children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiovascular anomalies in adults'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A three- to 11-fold increase mortality was also observed for pneumonia, diabetes, epilepsy, liver disease, and kidney disease.",
"     </li>",
"     <li>",
"      Mortality was increased for all karyotype groups, but was higher among patients with nonmosaic 45,X than 46,X mosaicism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations highlight the importance of preventive measures and careful monitoring for complications in both children and adults with Turner syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/20/32065?source=see_link\">",
"       \"Patient information: Turner syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1696801\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Turner syndrome (TS) must be suspected in any girl with short stature. Adult height is 20 cm below the mean female population if not treated with growth hormone.",
"     </li>",
"     <li>",
"      We recommend starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      therapy as soon as the height of a girl with Turner syndrome falls below the fifth percentile for age, which usually occurs between two and five years of age (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Height can be normalized in most patients using GH doses higher than standard doses used for GH deficiency. Individualization is essential. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Growth hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend beginning low-dose estrogen therapy at around age 12 years of age to permit a normal timing and pace of puberty without compromising adult height. Replacement is usually begun at doses between one-tenth and one-eighth of the adult replacement dose, and then increased gradually during the next two to four years. To optimize breast development, we suggest delaying progestin therapy for approximately two years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Estrogen therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There should be ongoing cardiac evaluation using echocardiography. Additionally, in older children and adults, MRIs are important and should be done every 5 to 10 years. Women with Turner syndrome are also at risk for aortic dissection. To minimize this risk, close cardiovascular monitoring is required in patients with a dilated ascending aorta (aortic size index &gt;2.0",
"      <span class=\"nowrap\">",
"       cm/m).",
"      </span>",
"      Evidence-based recommendations for managing these patients are not available, but we suggest that measures used in patients with Marfan syndrome, such as beta-blockers, exercise restriction, and aggressive blood pressure control may be appropriate in this setting as well. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiovascular anomalies in adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to cardiovascular problems, sensorineural hearing impairment, hypothyroidism, and metabolic syndrome are more frequent in TS in childhood and adulthood and require careful monitoring. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hearing loss'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Hypothyroidism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Metabolic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with Turner syndrome have premature ovarian failure (primary ovarian insufficiency). We suggest that these women continue estrogen-progestin therapy until the average age of menopause (50 to 51 years) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fertility can be achieved with in vitro fertilization with donor oocytes, but there are cardiovascular risks, most importantly aortic dissection. Cardiovascular evaluation is essential before considering trying to become pregnant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H523815943#H523815943\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/1\">",
"      Saenger P. Turner's syndrome. N Engl J Med 1996; 335:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/2\">",
"      Ostberg JE, Conway GS. Adulthood in women with Turner syndrome. Horm Res 2003; 59:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/3\">",
"      Taipale P, Hiilesmaa V, Salonen R, Yl&ouml;stalo P. Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med 1997; 337:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/4\">",
"      Gunther DF, Eugster E, Zagar AJ, et al. Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life. Pediatrics 2004; 114:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/5\">",
"      Koeberl DD, McGillivray B, Sybert VP. Prenatal diagnosis of 45,X/46,XX mosaicism and 45,X: implications for postnatal outcome. Am J Hum Genet 1995; 57:661.",
"     </a>",
"    </li>",
"    <li>",
"     Naeraa RW, Gravholt CH, Hansen J, et al. Mortality in Turner syndrome. In: Turner syndrome in a life span perspective: Research and clinical aspects, Albertsson-Wikland K, Ranke MB (Eds), Elsevier, Amsterdam 1995. p.323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/7\">",
"      Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007; 92:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/8\">",
"      G&oslash;tzsche CO, Krag-Olsen B, Nielsen J, et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994; 71:433.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/10\">",
"      Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84:4607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/11\">",
"      Reiter EO, Blethen SL, Baptista J, Price L. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome. J Clin Endocrinol Metab 2001; 86:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/12\">",
"      Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med 2011; 364:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/13\">",
"      Saenger P. Growth-promoting strategies in Turner's syndrome. J Clin Endocrinol Metab 1999; 84:4345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/14\">",
"      Ari M, Bakalov VK, Hill S, Bondy CA. The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome. J Clin Endocrinol Metab 2006; 91:4302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/15\">",
"      Sas TC, Cromme-Dijkhuis AH, de Muinck Keizer-Schrama SM, et al. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. J Pediatr 1999; 135:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/16\">",
"      Bondy CA, Van PL, Bakalov VK, Ho VB. Growth hormone treatment and aortic dimensions in Turner syndrome. J Clin Endocrinol Metab 2006; 91:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/17\">",
"      Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in turner syndrome. J Clin Endocrinol Metab 2008; 93:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/18\">",
"      Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ 2011; 342:d1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/19\">",
"      Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996; 81:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/20\">",
"      Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 1998; 132:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/21\">",
"      Chernausek SD, Attie KM, Cara JF, et al. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. J Clin Endocrinol Metab 2000; 85:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/22\">",
"      Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002; 87:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/23\">",
"      Pai GS, Leach DC, Weiss L, et al. Thyroid abnormalities in 20 children with Turner syndrome. J Pediatr 1977; 91:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/24\">",
"      Rosenfeld, RG, Tesch, LG, Rodriguez-Rigau, LJ, et al. Recommendations for diagnosis, treatment, and management of individuals with Turner syndrome. Endocrinologist 1994; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/25\">",
"      Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab 1993; 76:861.",
"     </a>",
"    </li>",
"    <li>",
"     Conway GS, et al. Adult Turner follow-up: The middlesex experience. In: Optimizing health care for Turner patients in the 21st century, Saenger P, Parquino AM (Eds), Elsevier, Amsterdam 2000. p.295.",
"    </li>",
"    <li>",
"     Ross JL, Reiss A, Freund L, et al. Estrogen effects on cognition and social function in Turner syndrome. In: Basic and clinical approach to Turner syndrome, Hibi I, Takano K (Eds), Excerpta Medica, Amsterdam 1993. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/28\">",
"      Ross JL, Roeltgen D, Feuillan P, et al. Use of estrogen in young girls with Turner syndrome: effects on memory. Neurology 2000; 54:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/29\">",
"      Ross JL, Roeltgen D, Feuillan P, et al. Effects of estrogen on nonverbal processing speed and motor function in girls with Turner's syndrome. J Clin Endocrinol Metab 1998; 83:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/30\">",
"      Ross JL, Stefanatos GA, Kushner H, et al. Persistent cognitive deficits in adult women with Turner syndrome. Neurology 2002; 58:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/31\">",
"      Ross JL, Roeltgen D, Stefanatos GA, et al. Androgen-responsive aspects of cognition in girls with Turner syndrome. J Clin Endocrinol Metab 2003; 88:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/32\">",
"      Ross JL, Mazzocco MM, Kushner H, et al. Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome. J Pediatr 2009; 155:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/33\">",
"      Devernay M, Ecosse E, Coste J, Carel JC. Determinants of medical care for young women with Turner syndrome. J Clin Endocrinol Metab 2009; 94:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/34\">",
"      Trolle C, Mortensen KH, Hjerrild BE, et al. Clinical care of adult Turner syndrome--new aspects. Pediatr Endocrinol Rev 2012; 9 Suppl 2:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/35\">",
"      Saenger P, Wikland KA, Conway GS, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001; 86:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/36\">",
"      Ranke MB, Saenger P. Turner's syndrome. Lancet 2001; 358:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/37\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/38\">",
"      Matura LA, Sachdev V, Bakalov VK, et al. Growth hormone treatment and left ventricular dimensions in Turner syndrome. J Pediatr 2007; 150:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/39\">",
"      Barren&auml;s ML, Nyl&eacute;n O, Hanson C. The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. Hear Res 1999; 138:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/40\">",
"      Hultcrantz M, Sylv&eacute;n L, Borg E. Ear and hearing problems in 44 middle-aged women with Turner's syndrome. Hear Res 1994; 76:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/41\">",
"      Hultcrantz M, Sylv&eacute;n L. Turner's syndrome and hearing disorders in women aged 16-34. Hear Res 1997; 103:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/42\">",
"      Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/43\">",
"      Kaneko N, Kawagoe S, Hiroi M. Turner's syndrome--review of the literature with reference to a successful pregnancy outcome. Gynecol Obstet Invest 1990; 29:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/44\">",
"      Press F, Shapiro HM, Cowell CA, Oliver GD. Outcome of ovum donation in Turner's syndrome patients. Fertil Steril 1995; 64:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/45\">",
"      Yaron Y, Ochshorn Y, Amit A, et al. Patients with Turner's syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Fertil Steril 1996; 65:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/46\">",
"      Foudila T, S&ouml;derstr&ouml;m-Anttila V, Hovatta O. Turner's syndrome and pregnancies after oocyte donation. Hum Reprod 1999; 14:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/47\">",
"      Bodri D, Vernaeve V, Figueras F, et al. Oocyte donation in patients with Turner's syndrome: a successful technique but with an accompanying high risk of hypertensive disorders during pregnancy. Hum Reprod 2006; 21:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/48\">",
"      Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey. Fertil Steril 2003; 80:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/49\">",
"      Practice Committee of the American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril 2006; 86:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/50\">",
"      Hreinsson JG, Otala M, Fridstr&ouml;m M, et al. Follicles are found in the ovaries of adolescent girls with Turner's syndrome. J Clin Endocrinol Metab 2002; 87:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/51\">",
"      B&ouml;sze P, T&oacute;th A, T&ouml;r&ouml;k M. Hormone replacement and the risk of breast cancer in Turner's syndrome. N Engl J Med 2006; 355:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/52\">",
"      Elsheikh M, Hodgson HJ, Wass JA, Conway GS. Hormone replacement therapy may improve hepatic function in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 55:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/53\">",
"      Stochholm K, Juul S, Juel K, et al. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006; 91:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14329/abstract/54\">",
"      Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Mortality in women with turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab 2008; 93:4735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7386 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14329=[""].join("\n");
var outline_f13_63_14329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1696801\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRENATAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFANTS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular anomalies in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Short stature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Growth hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7637360\">",
"      - Growth hormone with oxandrolone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Edema and keloid formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cognitive function and learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiovascular anomalies in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Abnormal liver enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Duration of use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hepatic function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1696801\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7386|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/44/22222\" title=\"algorithm 1\">",
"      Cardiovascular management Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7386|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/36/20046\" title=\"figure 1\">",
"      Long term GH in TS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/13/35024\" title=\"figure 2\">",
"      Cumulative risk of death Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/23/11644\" title=\"table 1A\">",
"      Treatment Turner I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/2/27691\" title=\"table 1B\">",
"      Treatment Turner II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/45/37596\" title=\"table 1C\">",
"      Treatment Turner III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/55/28540\" title=\"table 2\">",
"      Turner estrogen dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37880?source=related_link\">",
"      Management of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/20/32065?source=related_link\">",
"      Patient information: Turner syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_63_14330="Vasoocclusion in sickle cell disease";
var content_f13_63_14330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasoocclusion in sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Martin H Steinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/63/14330/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/63/14330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sickle cell disease (SCD; this designation includes homozygosity for hemoglobin S, compound heterozygosity for hemoglobins S and C, compound heterozygosity for hemoglobin S and beta thalassemia, plus other less common genotypes) is a typical Mendelian disorder. It is associated with hypoxia-induced polymerization of the abnormal hemoglobin S molecule, followed by red blood cell sickling, with resultant microvascular occlusion (vasoocclusion) clinically manifested most often as an acute painful episode or \"crisis\", but with many other acute and chronic complications.",
"   </p>",
"   <p>",
"    However, numerous features of SCD are not accounted for by polymerization-based explanations alone, including the high degree of clinical heterogeneity among patients with identical genotypes, the unpredictable occurrence of acute vasoocclusive episodes, and the different rate of more chronic complications. This variance in phenotypic expression is due partly to the modulating effects of numerous modifier (epistatic) genes, and environmental and psychosocial factors. Recognition of these polymerization- independent mechanisms has placed the sickle cell disorders into the broader area of vascular disease, in which the interaction between sickle cells and the vascular endothelium assumes primary importance. Interrupting such interactions may provide a worthwhile therapeutic strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=see_link\">",
"     \"The endothelium: A primer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss those factors underlying the process of sickle vasoocclusion. Discussions of the overall process of hemoglobin S polymer formation and the effects of modulatory genes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    .) Treatment of the painful vasoocclusive crisis in adults with sickle cell disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=see_link\">",
"     \"Acute pain management in adults with sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRADITIONAL POLYMER-BASED CONCEPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attribution of all aspects of SCD to hemoglobin polymerization-related events evolved to a great extent from circumstantial evidence linking the peculiar shape of sickle red cells, abnormal hemoglobin S (HbS) solubility, blood viscosity, structure of the HbS polymer, and impaired rheologic properties of sickle cell suspensions. The relationships among these abnormalities have been unified into an enticing totality not completely supported by the clinical realities of the disease. Previous reviews include references to these primary studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The knowledge gained of the structure of HbS polymer, its intermolecular contact points [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/3\">",
"     3",
"    </a>",
"    ], the kinetic and thermodynamic constraints of polymerization, and the modulating influences of fetal hemoglobin (HbF) on the polymerization process were used to support attribution of all features of SCD to polymerization-related events. As further support for the importance of polymerization, therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , employed to elevate HbF levels, was found to significantly reduce the frequency of pain, acute chest syndrome, and transfusion in children and adults with SCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H3#H3\">",
"     \"Specific therapies for sickle cell disease\", section on 'Reactivating fetal hemoglobin synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical examples providing the best evidence for polymerization-induced sickling as the cause of vasoocclusion are the two sickle cell disorders HbSC disease and HbS with gene deletion hereditary persistence of fetal hemoglobin (HbS-HPFH):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The marked cellular dehydration seen in HbSC red cells results in increased intraerythrocytic concentrations of HbS which support polymerization, causing symptoms of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The virtual absence of vasoocclusive complications in HbS-HPFH is due to pancellular high levels of HbF [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/6\">",
"       6",
"      </a>",
"      ], inhibiting polymerization and cellular sickling [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the clinical improvement observed following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    has been attributed to increased levels of HbF [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/9\">",
"     9",
"    </a>",
"    ], hydroxyurea also reduces the number of poorly deformable dense sickle cells, highly adhesive sickle reticulocytes, and leukocytes, any one of which might alter disease severity independent of the sickling phenomenon, although all of these observations might be secondary to higher HbF levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sickling",
"    </span>",
"    &nbsp;&mdash;&nbsp;That cell sickling is unlikely to be the singular effector of painful vasoocclusion is supported by a lack of correlation between painful events and the number of dense red cells, those cells most prone to polymerization.",
"   </p>",
"   <p>",
"    The initiation of vasoocclusion is a complex highly stochastic process and the usual pain crises seen in SCD cannot be ascribed to hypoxia-induced bursts of cell sickling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with SCD do not experience systematic fluctuations in conditions that enhance hemoglobin polymerization and sickling (eg, hypoxemia, acidosis). Indeed, there is a lack of evidence for increased pain crises in subjects with concomitant sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/11\">",
"     11",
"    </a>",
"    ], a condition associated with periodic hypoxemia.",
"   </p>",
"   <p>",
"    Further evidence against episodes of acute cell sickling accounting vasoocclusive episodes derives from consideration that the average adult has a blood volume of approximately five liters and a cardiac output of five",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    which dictates that the average red cell must be exposed to hypoxic conditions on the venous side of the circulation approximately once per minute. Thus, the process of cell sickling must be incessant, as suggested by the presence in the blood of sickle cells at all times, even in the absence of an acute vasoocclusive event, and not dependent on accelerated HbS polymerization to initiate a bout of vasoocclusion. Despite well-defined conditions in which vasoocclusion can be attributed directly to cell sickling, such as acute hypoxia and hypertonicity, in most circumstances vasoocclusion is preceded by events independent of sudden HbS polymerization, although the nature of such events is usually unknown.",
"   </p>",
"   <p>",
"    Therefore, HbS polymerization provides only a first approximation of clinical severity, and that additional factors are likely to determine the temporal and interpatient variability so characteristic of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. It has therefore been concluded that the onset of cell sickling is neither a necessary and sufficient condition nor the primary initiator of the common painful episode [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Microvascular obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second controversial issue has to do with the assumption that the pathophysiology of SCD involves microvascular obstruction. This is based on the expectation that the smallest vessels should be most susceptible to occlusion. However, studies of animal models and human subjects have identified several sites of impaired blood flow and vasoocclusion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rat mesocecum capillaries perfused with human sickle cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Small vessels of autopsy and biopsy specimens [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Capillaries of the nailbed [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/17\">",
"       17",
"      </a>",
"      ] and forearm skin [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Large arteries of sickle cell patients with stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arteriolar-capillary bifurcations and venular junctions in microvascular flow models [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-capillary venules of rat mesocecums perfused with human sickle cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/15\">",
"       15",
"      </a>",
"      ] and of mucosal-intestinal tissues of transgenic knockout sickle cell mice [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there are numerous sites of initiation of vasoocclusion. It seems reasonable to suggest that the initiation of vasoocclusion varies over time and place according to differences in blood shear rates and endothelial activation states [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/22\">",
"     22",
"    </a>",
"    ], vascular bed characteristics, vascular tone, differential responses to endothelial cell agonists, and varying utilization of cellular and soluble adhesion molecules. These subjects are discussed in greater detail below (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Multiple pathway model'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The steady state",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third issue with the traditional polymerization-based doctrine pertains to whether there is normal steady-state blood flow separate from episodes of acute vasoocclusion. Clinical observation suggests a baseline state in which patients with SCD are relatively asymptomatic until they experience an event that triggers an episode of acute painful vasoocclusion. A lack of overt clinical events, however, cannot be equated with the abeyance of sickle vasculopathy.",
"   </p>",
"   <p>",
"    Extensive biochemical data have blurred the distinction between a so-called steady state and acute vasoocclusion in SCD. Several biochemical markers are elevated in the blood of patients with SCD who have not had a recent acute, painful episode [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The list of such markers found to be elevated in patients with SCD is extensive, and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C-reactive protein",
"     </li>",
"     <li>",
"      Fibrinogen and other acute phase reactants",
"     </li>",
"     <li>",
"      Tumor necrosis factor-alpha (TNF-a)",
"     </li>",
"     <li>",
"      Interleukin (IL)-1, IL-2, and IL-2 receptor",
"     </li>",
"     <li>",
"      Interferon-gamma",
"     </li>",
"     <li>",
"      Markers of activity of the endothelial cell agonist, thrombin",
"     </li>",
"     <li>",
"      Endotoxin",
"     </li>",
"     <li>",
"      Soluble vascular cell adhesion molecule-1 (sVCAM-1)",
"     </li>",
"     <li>",
"      Soluble intercellular adhesion molecule-1 (sICAM-1)",
"     </li>",
"     <li>",
"      Circulating endothelial cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal levels of activators of endothelial cells, macrophages, and other blood cells have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and it has been suggested that levels of cytokines and other cell agonists may be used as a measure of clinical severity in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While fluctuating levels of inflammatory markers during steady state may be indicative of subclinical vasoocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/29\">",
"     29",
"    </a>",
"    ], it is uncertain whether these fluctuations are of pathophysiologic importance. Indeed, there may be little difference between the physiologic conditions existing during steady state and the acute vasoocclusive episode. Initiation of an acute pain crisis could simply reflect a slight imbalance in circulatory homeostasis, derived from a mere stochastic accumulation of input from several physiologic mechanisms, a phenomenon that has been referred to as \"stochastic stasis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considering the remarkable number of potentially relevant mechanisms that have been identified with vasoocclusion (",
"    <a class=\"graphic graphic_table graphicRef74933 \" href=\"UTD.htm?15/19/15675\">",
"     table 1",
"    </a>",
"    ), it seems unreasonable to postulate only one pathophysiologic mechanism. Rather, it is plausible that mechanisms underlying vasoocclusion vary with time and anatomic site, and also vary among patients. Certainly there are relevant differences among distinct vascular beds, as shown by the functional heterogeneity of endothelial cells from large and small vessel sources and by organ to organ differences in the microvasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=see_link&amp;anchor=H1854496#H1854496\">",
"     \"The endothelium: A primer\", section on 'Endothelial heterogeneity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Organ-specific vasoocclusive mechanisms might also provide a possible explanation for the greater prevalence of retinopathy in patients with HbSC disease and osteonecrosis in those with sickle cell anemia and coexisting alpha thalassemia, although other explanations for these observations, such as the enhanced circulatory competence of sickle erythrocytes in these genotypes, are also reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/1\">",
"     1",
"    </a>",
"    ]. Vasoocclusive mechanisms could differ according to the organ complication under study and data obtained during acute painful episodes may not reflect the same mechanisms as vasoocclusion in other organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MULTIPLE PATHWAY MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prospect of multiple pathophysiologies underlying vasoocclusion implies that it may always involve several processes, and that one or more mechanisms may predominate under different clinical circumstances. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation may enhance leukocyte interactions with the endothelium to impede microvascular flow and promote sickling",
"     </li>",
"     <li>",
"      Activation of macrophage tissue factor may activate platelets, coagulation, and endothelial cells",
"     </li>",
"     <li>",
"      Clinical dehydration or activation of endothelial cells and platelets may elevate levels of thrombospondin or von Willebrand factor to mediate red cell adhesion to the endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regional hypoxia may induce the expression of endothelial cell P-selectin to enhance the adhesion of sickle cells as well as heterocellular interactions with platelets and neutrophils.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Red blood cells",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Microvascular transit time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The belief that vasoocclusive events are caused by sudden episodes of cellular deoxygenation and sickling does not reconcile with the knowledge that under normal conditions the average red blood cell is deoxygenated at least once a minute. With the passage from the arterial to the venous circulation, substantial numbers of cells become grossly sickled, and, in some cells, the accumulation of membrane damage renders them irreversibly sickled regardless of the physical state of their hemoglobin molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, sickling is not intermittent but constant and incessant, perhaps with each cell sickling to some extent an average of nearly 1500 times per day and dependent on the cellular concentration of HbF. However, the kinetics of polymerization demonstrate a delay time between the generation of deoxy-HbS and polymer formation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/10\">",
"     10",
"    </a>",
"    ], resulting in many cells failing to sickle until they have passed into a vessel too large to be occluded by sickled cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link&amp;anchor=H15#H15\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\", section on 'Intracellular studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The delicate balance between the transit time of cells through the microcirculation and the delay times to polymerization can be altered by factors that delay transit time, such as poor red cell deformability or increased endothelial adhesivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/10,36\">",
"     10,36",
"    </a>",
"    ]. In addition, erythrocyte membranes may influence polymerization by controlling erythrocyte cation transport, cellular hydration, and intraerythrocytic concentrations of HbS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/37\">",
"     37",
"    </a>",
"    ], and provide nucleation sites for HbS polymerization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Blood viscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the hematocrit of sickle cell blood is increased in vitro, even with the addition of non-sickle red cells, its viscosity is increased and its flow properties impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/38\">",
"     38",
"    </a>",
"    ]. This phenomenon provides the basis for the recommendation to avoid post-transfusion hematocrit levels much greater than 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The importance of blood viscosity on vasoocclusive events is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Painful vasoocclusion often follows the cessation of oxygen inhalation, coinciding with increased hematocrit levels and elevated numbers of leukocytes, irreversibly sickled cells, and reticulocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pain crisis has been observed when carbon monoxide exposure resulted in hematocrit levels above baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The beneficial effects of alpha thalassemia on deformability of individual sickle red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/43\">",
"       43",
"      </a>",
"      ] ameliorate the severity of anemia by prolonging erythrocyte lifespan [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/44\">",
"       44",
"      </a>",
"      ]. However, the resultant higher hematocrit levels impair flow properties of sickle cell blood [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/45\">",
"       45",
"      </a>",
"      ], which is associated with more frequent retinopathy, osteonecrosis, acute chest syndrome, and painful vasoocclusion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a positive association between cellular deformability and frequency of pain (see below) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dense irreversibly sickled cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most dense sickle red cells, as a result of their high intraerythrocytic HbS concentration, are least deformable, most prone to contain HbS polymer, and most likely to encounter difficulty traversing the microcirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/48\">",
"     48",
"    </a>",
"    ]. Despite this, the frequency of vasoocclusive events in SCD correlates with cells of better deformability rather than with those of poor deformability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], an association that is consistent with dense irreversibly sickled cells not playing a rate-limiting, direct gate-keeping role in the vasoocclusive process.",
"   </p>",
"   <p>",
"    The implication that dense cells may secondarily log-jam behind an obstruction, rather than initiate occlusion has been documented by studies of human sickle cells perfused into rat vessels. The more adhesive, low density sickle cells adhered to the vascular endothelium to initiate occlusion, and poorly deformable, dense cells completed the occlusive event (",
"    <a class=\"graphic graphic_figure graphicRef80615 \" href=\"UTD.htm?10/44/10945\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dense red cell fractions increase just before a painful episode and decrease during the early phase of the crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. It has not been determined whether this initial increase in the dense cell fraction is caused by an accumulation of dense cells or a depletion of less dense cells, or whether the subsequent decrease in dense cell fraction is due to depletion of the densest cells or expansion of low density cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other erythrocytic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other erythrocyte-specific mechanisms may influence the processes associated with vasoocclusion. The concentration-dependent lowered oxygen affinity and elevated intraerythrocytic 2,3-BPG levels each stabilize the deoxy conformation of HbS, facilitating the release of oxygen and promotion of polymerization, cellular sickling, and vasoocclusion.",
"   </p>",
"   <p>",
"    A little known mechanism relevant to vasoocclusion is a negative feedback loop involving hemolysis and polymerization. Heme catabolism is the only process in mammals by which carbon monoxide (CO) is generated. Red cell destruction increases the endogenous production of CO, increasing the levels of carboxy-HbS, a liganded form of HbS with increased oxygen affinity, increased solubility, and reduced polymerization tendency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/52\">",
"     52",
"    </a>",
"    ]. This mechanism, through which hemolysis might modulate sickle cell pathobiology, is consistent with the observation of an increasing hematocrit in a SCD patient with carboxyhemoglobinemia due to CO exposure. It was presumed that the high oxygen affinity of these sickle erythrocytes both inhibited HbS polymerization and stimulated erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coagulation, hemostasis, and platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased thrombin generation and platelet activation could reflect the hypercoagulable state found in sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Induction of tissue factor expression on circulating monocytes might be the primary trigger of hemostatic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/53\">",
"     53",
"    </a>",
"    ]. In principal, activation of coagulation and platelets should result in conditions that facilitate vasoocclusion. Thrombus formation, lipid surfaces that accelerate coagulation, cytoadhesive proteins that mediate red cell adherence to the endothelium, reduction in the anticoagulant proteins S and C, and factors that modulate endothelial cell function and surface properties have all been detected in patients with SCD.",
"   </p>",
"   <p>",
"    Endothelial dysfunction, resulting from vascular injury induced by adherent sickle cells and leukocytes, and by biologic modifiers (eg, cytokines, hypoxia,",
"    <span class=\"nowrap\">",
"     ischemia/reperfusion,",
"    </span>",
"    oxidative radicals) and liberation of heme with depletion of nitric oxide secondary to intravascular hemolysis, may also play a role in this hypercoagulable state [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. It is also possible that most of these abnormalities are secondary to sickle vasoocclusion and are not primary factors in its etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=see_link&amp;anchor=H1854652#H1854652\">",
"     \"The endothelium: A primer\", section on 'Procoagulant properties'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is equally plausible that the primary event may be the expression of P-selectin by endothelial cells as a result of hypoxic or",
"    <span class=\"nowrap\">",
"     ischemia/reperfusion",
"    </span>",
"    injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/58,61,62\">",
"     58,61,62",
"    </a>",
"    ]. The overall contribution of coagulation to vasoocclusion is unimpressive and oral anticoagulants or antiplatelet therapy appear to provide little or no benefit, although few well-conducted trials have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Blood vessels",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vascular endothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multitude of adhesion molecules displayed on endothelial cells and the vascular matrix, and the adhesion of sickle cells to these molecules have been the subject of considerable investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/31,67\">",
"     31,67",
"    </a>",
"    ]. For example, the increased adhesion of sickle cells to cultured endothelial cells infected with herpes simplex virus in vitro suggests that clinical viral infection might initiate vasoocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other examples of activated endothelial expression of adhesion molecules include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expression of P-selectin by endothelial cells as a result of hypoxic or",
"      <span class=\"nowrap\">",
"       ischemia/reperfusion",
"      </span>",
"      injury [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/58,61,62\">",
"       58,61,62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased expression of intracellular adhesion molecule-1 (ICAM-1) on retinal vessels of sickle cell patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased expression of P-selectin by endothelial cells in mouse models of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 160 unselected adult patients with sickle cell disease in steady state, elevated levels of soluble adhesion markers (sICAM-1, sE-selectin, sVCAM-1), signifying endothelial dysfunction or inflammation with endothelial activation, correlated with severity of pulmonary hypertension and risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of agents (eg, anti-selectins, Pentosan) to reduce endothelial activation and vascular occlusion are in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. In one such study, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    inhibited the progression of pneumococcal disease by down-modulating E-selectin on pulmonary and vascular endothelial cells, reducing the damage to lung tissue otherwise associated with increased leukocyte recruitment to the infected lung [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of in vitro microvasculature models, including one lined with vascular endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/77\">",
"     77",
"    </a>",
"    ], may help in the understanding of microvascular occlusion and thrombosis in sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Matrix molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelial matrix of intact vessels is not exposed to circulating red cells, but certain biological response modifiers (eg, histamine, thrombin) cause contraction of endothelial cells and resultant exposure of matrix within the intercellular gaps. However, large increases in the area of exposed matrix are associated with only small increases in the adhesion of sickle cells to uncovered matrix in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/80\">",
"     80",
"    </a>",
"    ]. The possibility that sickle cell adhesion is mediated by the simultaneous action of matrix and endothelial molecules suggests an explanation for this discrepancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more likely explanation for the observation that sickle cells adhere to the edges of endothelial cells when gaps are induced is that endothelial cell contraction results in the redistribution of integrins from the abluminal to luminal surface of endothelial cells where they are available for adhesion of sickle cells (",
"    <a class=\"graphic graphic_figure graphicRef57423 \" href=\"UTD.htm?36/13/37075\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/80,82\">",
"     80,82",
"    </a>",
"    ]. The differences in the effects of oral anticoagulants and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    on frequency of pain may relate to the differential effects of these treatments on blocking P-selectin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/63,83,84\">",
"     63,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The growing list of erythroid and vascular adhesive molecules that participate in sickle cell adhesion bears a striking resemblance to those active in leukocyte adhesion during inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. In the latter process, adhesion is initiated by the action of selectins, and in the absence of these molecules inflammation is deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/88\">",
"     88",
"    </a>",
"    ]. As an example, P-selectin on activated endothelial cells is important to the adhesion of sickle cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/89,90\">",
"     89,90",
"    </a>",
"    ] and to microvascular occlusion in sickle cell mice in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/91\">",
"     91",
"    </a>",
"    ]. These data support a function of endothelial cell P-selectin in sickle cell adhesion and vasoocclusion that is similar to its critical role in leukocyte adhesion and inflammation (",
"    <a class=\"graphic graphic_figure graphicRef57423 \" href=\"UTD.htm?36/13/37075\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a mouse model, E-selectin generated signals that were transduced by E-selectin ligand-1 and induced polarized, activated alpha(M)beta(2) integrin clusters at the leading edge of crawling neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/92\">",
"     92",
"    </a>",
"    ]. This captured circulating erythrocytes or platelets and, in a mouse model of SCD, allowed the capture of erythrocytes by this integrin leading to acute lethal vasoocclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Vasoregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoregulatory factors that alter microvascular dynamics, vascular tone, and blood flow probably influence vasoocclusion by affecting the velocity of blood flow and the microcirculatory transit time. These effects could initiate or contribute to the evolution of vasoocclusion already in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/93\">",
"     93",
"    </a>",
"    ]. Relevant observations on vasoregulatory influences in patients with sickle cell disease include oscillatory microvascular flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/18\">",
"     18",
"    </a>",
"    ] and similar flow intermittence during reactive hyperemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Production of the potent vasoconstrictor endothelin (ET-1) is induced by hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/94\">",
"     94",
"    </a>",
"    ] and by exposure of endothelial cells to sickled cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/95\">",
"     95",
"    </a>",
"    ], as well as by placental growth factor, levels of which are increased in SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/96\">",
"     96",
"    </a>",
"    ]. Increased endothelin levels are seen in the plasma of patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/97\">",
"     97",
"    </a>",
"    ], and are further increased during pain crises [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/98\">",
"     98",
"    </a>",
"    ] and the acute chest syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/99\">",
"     99",
"    </a>",
"    ]. These findings support a potentially detrimental role of endothelin-induced vasoconstriction in prolonging the transit time of sickle cells through the microvasculature, and suggest that endothelin antagonists may have a role in ameliorating SCD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of the endothelin receptor antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      prevents hypoxia-induced mortality and morbidity in a mouse model of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/100\">",
"       100",
"      </a>",
"      ]. A clinical trial of bosentan in sickle cell pulmonary hypertension was halted because of poor recruitment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H26#H26\">",
"       \"Treatment of pulmonary hypertension in adults\", section on 'Bosentan'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       Hydroxyurea",
"      </a>",
"      treatment of children with SCD has resulted in a decreased concentration of circulating ET-1, although this was not correlated with the hydroxyurea-induced increase HbF levels [",
"      <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of the potent vasodilatory substance nitric oxide (NO) on sickle cell pathophysiology are extraordinarily complex. In addition to its vasodilatory activity, NO also modulates hemoglobin function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/103\">",
"     103",
"    </a>",
"    ], blocks the activation of platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/104\">",
"     104",
"    </a>",
"    ], and attenuates the adhesivity of endothelial cells for sickle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interactions between NO and hemoglobin have come under increased scrutiny [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/106\">",
"     106",
"    </a>",
"    ]. The apparently limited bioavailability of NO in SCD may be related to depleted stores of the NO precursor L-arginine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/107\">",
"     107",
"    </a>",
"    ], sequestration of plasma NO by free hemoglobin engendered by intravascular hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/108-111\">",
"     108-111",
"    </a>",
"    ], oxidative inactivation of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/112\">",
"     112",
"    </a>",
"    ], increased levels of arginase [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/113\">",
"     113",
"    </a>",
"    ], or failure to deliver NO to the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/114\">",
"     114",
"    </a>",
"    ]. Such loss of NO regulation, associated especially with high degrees of intravascular hemolysis, has been associated with endothelial dysfunction and end-organ vasculopathy in SCD, including leg ulceration, priapism, pulmonary hypertension, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/110,115,116\">",
"     110,115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasoregulatory actions of catecholamines must also be considered as a potential component of the association between vasoocclusive crisis and \"stress.\" Additional studies suggest that epinephrine-activated sickle erythrocytes also induce lymphocyte and monocyte adherence to the endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Psychosocial factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sickle cell adhesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal adhesivity of sickle red cells for the vascular endothelium has been documented using several in vitro and in vivo methods. Cytokines, chemokines, histamine, thrombin, hypoxia, and heme, activated monocytes and platelets, and the presence of phosphatidylserine and sulfatide on the red cell surface have all been implicated in this increased endothelial adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. A positive relationship between clinical severity of SCD and the degree of sickle cell adhesivity has demonstrated the pathophysiologic relevance of this phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/31,120\">",
"     31,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of vasoocclusion by the interactions of a more adhesive population of sickle cells to the vascular endothelium makes a strong case for the fundamental importance of this event [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/20\">",
"     20",
"    </a>",
"    ]. This may also explain the fractional reduction of low-density, more adherent sickle cells during the initial stages of pain crisis as they stick to the endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and the observed positive correlation between pain frequency and improved sickle cell deformability secondary to an increase in the more deformable low density reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Reticulocytes have the capacity for receptor-mediated interactions with adhesive molecules in the plasma and vasculature, and are the probable initiators of vasoocclusion (",
"    <a class=\"graphic graphic_figure graphicRef80615 \" href=\"UTD.htm?10/44/10945\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional data suggest that patients having a greater proportion of receptor-bearing reticulocytes are more susceptible to adherence-mediated vasoocclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. However, reticulocytes are not the only abnormally adhesive sickle cells; all subpopulations of sickle cells are abnormally adhesive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/31\">",
"     31",
"    </a>",
"    ]. Many different molecules mediate vascular adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/85-87\">",
"     85-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An adhesogenic mechanism in which the adhesion of sickle cells to endothelial cells is induced by epinephrine may explain the clinical observation that pain crises are often stress-related [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/123-125\">",
"     123-125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Leukocytes and inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The slow microvascular passage of the polymorphonuclear leukocyte, which has much lower deformability than normal red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/126\">",
"     126",
"    </a>",
"    ], suggests that enhanced",
"    <span class=\"nowrap\">",
"     leukocyte/endothelial",
"    </span>",
"    interaction during inflammation, or secondary to an interaction between sickle red cells and epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/117,125\">",
"     117,125",
"    </a>",
"    ], might provide a nidus of adhesion to allow either red cell sickling or adhesion of red cells proximal to the area of retarded flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/22,127-129\">",
"     22,127-129",
"    </a>",
"    ]. In support of this hypothesis, an intriguing report concluded that sickle cell adhesion and vasoocclusion in normal mice transplanted with bone marrow from transgenic knockout sickle cell mice and then treated with high doses of the endothelial cell agonist TNF-alpha were secondary to the initial adhesion of leukocytes to the vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical support for the importance of leukocytes in the vasoocclusive process derives from the higher mortality rate in SCD patients with higher white cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/131\">",
"     131",
"    </a>",
"    ] and the occurrence of fatal or severe vasoocclusive events following extreme leukocytosis induced by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) in patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/132\">",
"     132",
"    </a>",
"    ]. Earlier reports of an association between the beneficial effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and reduced leukocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/133\">",
"     133",
"    </a>",
"    ] have not been substantiated, and might have been the result of an experimental design that titrated the hydroxyurea dose to the leukocyte count. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the management of sickle cell disease\", section on 'Granulocyte colony-stimulating factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional clinical support comes from the coincidence between painful vasoocclusion occurring after the cessation of oxygen inhalation with increased numbers of white blood cells, but also with increased numbers of reticulocytes and irreversibly sickled cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene expression profiles of circulating blood mononuclear cells have suggested an intense oxidant and inflammatory nature of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/134\">",
"     134",
"    </a>",
"    ]. Further, in a study of 70 children with SCD, high-sensitivity C-reactive protein levels, a marker of low-grade systemic inflammation, emerged as the most significant laboratory correlate of hospitalization for pain or vasoocclusive events [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an in vivo animal model of SCD, the use of intravenous immunoglobulin (IVIG) following an inflammatory stimulus was shown to rapidly reduce adherent leukocyte numbers and dramatically inhibit interactions between WBCs and RBCs, resulting in improved microcirculatory blood flow and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other support for the importance of heterocellular interactions to sickle cell vasoocclusion derives from reports of platelet activation and the presence of circulating platelet-sickle cell complexes in patients with SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/137\">",
"     137",
"    </a>",
"    ], although at this time there is no evidence for the contribution of platelets to vasoocclusion. The overall contribution of platelets to vasoocclusion is called into doubt by the lack of effect on pain frequency of treatment with platelet inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/138,139\">",
"     138,139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the red cell is a perfect osmometer, the osmotic effect experienced by sickle red cells during hyperosmolar clinical dehydration or in the renal medulla raises intraerythrocytic concentrations of HbS and promotes HbS polymerization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/140\">",
"     140",
"    </a>",
"    ]. Clinical acidosis is also a potentially perilous situation, since low pH levels reduce the solubility of HbS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/141\">",
"     141",
"    </a>",
"    ] and dehydrate sickle red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/142\">",
"     142",
"    </a>",
"    ]. Certain of the molecular mechanisms of sickle cell adhesion to the vascular endothelium are mediated by bridging plasma protein molecules, the concentrations of which fluctuate as acute phase reactants.",
"   </p>",
"   <p>",
"    Organ-specific differences in plasma pH and pO2 may also influence vasoocclusion. The low levels of pH and pO2 in the spleen and renal medulla, plus the hypertonic plasma environment of the latter, account for the impaired urine concentrating ability and splenic infarcts that occur almost universally in patients with SCD (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"UTD.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ), and even in some individuals with sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=see_link&amp;anchor=H5#H5\">",
"     \"Renal manifestations of sickle cell disease\", section on 'pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial factors contributing to the pain of acute vasoocclusive crises strongly define SCD. These include perception of pain, coping skills, personality, mood, and relationships with the health care system. The conventional notion that pain crises are associated with psychological stress may be explained physiologically, in part, by epinephrine-enhanced adhesivity of sickle erythrocytes to the vascular wall [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/123,125\">",
"     123,125",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by the observation that epinephrine-activated sickle erythrocytes induce adhesion of lymphocytes and monocytes to vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Vasoregulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, the pain- or emotion-stimulated release of vasoactive substances that transmit and modulate neurologic signals from painful stimuli may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/145\">",
"     145",
"    </a>",
"    ]. Accordingly, painful experiences and their accompanying morbidity can be modulated by psychological intervention in patients lacking adequate coping strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A great many processes have been identified that are important to the pathophysiology of sickle cell vasoocclusion, and it is clear that these interrelated processes do not occur in isolation. Vasoocclusion may vary with the state of the vascular bed and numerous other variables, with no boundary between \"steady state\" and acute vasoocclusion.",
"   </p>",
"   <p>",
"    While defining causality remains an elusive goal, determining the contributions of specific events will establish their pathogenic importance and potential as targets for the rational treatment of patients with sickle cell disease. Improved understandings have already suggested new therapeutic considerations, such as anti-adhesive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/63/14330/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], and progress in defining pathophysiological mechanisms is predicted to yield additional treatment options.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Embury SH, Vichinsky EP. Sickle cell disease. In: Hematology: Basic Principles and Practice, Hoffman RR, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/2\">",
"      Embury SH. The not-so-simple process of sickle cell vasoocclusion. Microcirculation 2004; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/3\">",
"      Bookchin RM, Nagel RL. Interactions between human hemoglobins: sickling and related phenomena. Semin Hematol 1974; 11:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/4\">",
"      Bunn HF, Noguchi CT, Hofrichter J, et al. Molecular and cellular pathogenesis of hemoglobin SC disease. Proc Natl Acad Sci U S A 1982; 79:7527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/5\">",
"      Fabry ME, Kaul DK, Raventos-Suarez C, et al. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences. J Clin Invest 1982; 70:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/6\">",
"      CONLEY CL, WEATHERALL DJ, RICHARDSON SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/7\">",
"      Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem 1977; 252:3414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/8\">",
"      Sewchand LS, Johnson CS, Meiselman HJ. The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes. Blood Cells 1983; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/9\">",
"      Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/10\">",
"      Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990; 40:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/11\">",
"      Brooks LJ, Koziol SM, Chiarucci KM, Berman BW. Does sleep-disordered breathing contribute to the clinical severity of sickle cell anemia? J Pediatr Hematol Oncol 1996; 18:135.",
"     </a>",
"    </li>",
"    <li>",
"     Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Pathogenesis of vasoocclusion. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/13\">",
"      Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? Br J Haematol 2007; 139:173.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrone FA, Cho MR, Bishop MF. Can a successful mechanism for HbS gelation predict sickle cell crisis?. In: Approaches to the Therapy of Sickle Cell Anemia, Beuzard Y, Charache S, Galacteros F (Eds), Les Editions Inserm, Paris 1985. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/15\">",
"      Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A 1989; 86:3356.",
"     </a>",
"    </li>",
"    <li>",
"     Song J. Pathology of Sickle Cell Disease, Thomas, Springfield 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/17\">",
"      Lipowsky HH, Sheikh NU, Katz DM. Intravital microscopy of capillary hemodynamics in sickle cell disease. J Clin Invest 1987; 80:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/18\">",
"      Rodgers GP, Schechter AN, Noguchi CT, et al. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med 1984; 311:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/19\">",
"      Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972; 287:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/20\">",
"      Kaul DK, Fabry ME, Nagel RL. Erythrocytic and vascular factors influencing the microcirculatory behavior of blood in sickle cell anemia. Ann N Y Acad Sci 1989; 565:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/21\">",
"      Embury SH, Mohandas N, Paszty C, et al. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest 1999; 103:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/22\">",
"      Wagner MC, Eckman JR, Wick TM. Sickle cell adhesion depends on hemodynamics and endothelial activation. J Lab Clin Med 2004; 144:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/23\">",
"      Singhal A, Doherty JF, Raynes JG, et al. Is there an acute-phase response in steady-state sickle cell disease? Lancet 1993; 341:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/24\">",
"      Stuart J, Stone PC, Akinola NO, et al. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Pathol 1994; 47:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/25\">",
"      Taylor SC, Shacks SJ, Qu Z. In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc 1999; 91:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/26\">",
"      Bourantas KL, Dalekos GN, Makis A, et al. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998; 61:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/27\">",
"      Wun T. The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy. Hematology 2001; 5:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/28\">",
"      Schnog JJ, Lard LR, Rojer RA, et al. New concepts in assessing sickle cell disease severity. Am J Hematol 1998; 58:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/29\">",
"      Akinola NO, Stevens SM, Franklin IM, et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. J Clin Pathol 1992; 45:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/30\">",
"      Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991; 77:214.",
"     </a>",
"    </li>",
"    <li>",
"     Hebbel RP, Mohandas N. Sickle cell adherence. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.217.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/32\">",
"      Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/33\">",
"      Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003; 100:10623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/34\">",
"      Chen J, Hobbs WE, Le J, et al. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 2011; 117:3680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/35\">",
"      Serjeant GR, Petch MC, Serjeant BE. The in vivo sickle phenomenon: a reappraisal. J Lab Clin Med 1973; 81:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/36\">",
"      Higgins JM, Eddington DT, Bhatia SN, Mahadevan L. Sickle cell vasoocclusion and rescue in a microfluidic device. Proc Natl Acad Sci U S A 2007; 104:20496.",
"     </a>",
"    </li>",
"    <li>",
"     Brugnara C. Cation homeostasis. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, and Steinberg MH (Eds), Raven Press, New York 1994. p.173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/38\">",
"      Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987; 27:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/39\">",
"      Schmalzer E, Chien S, Brown AK. Transfusion therapy in sickle cell disease. Am J Pediatr Hematol Oncol 1982; 4:395.",
"     </a>",
"    </li>",
"    <li>",
"     Vichinsky E. Transfusion. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.781.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/41\">",
"      Embury SH, Garcia JF, Mohandas N, et al. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med 1984; 311:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/42\">",
"      Charache S, de la Monte S, MacDonald V. Increased blood viscosity in a patient with sickle cell anemia. Blood Cells 1982; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/43\">",
"      Embury SH, Clark MR, Monroy G, Mohandas N. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest 1984; 73:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/44\">",
"      Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/45\">",
"      Serjeant BE, Mason KP, Kenny MW, et al. Effect of alpha thalassaemia on the rheology of homozygous sickle cell disease. Br J Haematol 1983; 55:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/46\">",
"      Ballas SK, Larner J, Smith ED, et al. Rheologic predictors of the severity of the painful sickle cell crisis. Blood 1988; 72:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/47\">",
"      Lande WM, Andrews DL, Clark MR, et al. The incidence of painful crisis in homozygous sickle cell disease: correlation with red cell deformability. Blood 1988; 72:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/48\">",
"      Clark MR, Mohandas N, Shohet SB. Deformability of oxygenated irreversibly sickled cells. J Clin Invest 1980; 65:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/49\">",
"      Akinola NO, Stevens SM, Franklin IM, et al. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol 1992; 81:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/50\">",
"      Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992; 79:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/51\">",
"      Fabry ME, Benjamin L, Lawrence C, Nagel RL. An objective sign in painful crisis in sickle cell anemia: the concomitant reduction of high density red cells. Blood 1984; 64:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/52\">",
"      Coburn RF, Williams WJ, Kahn SB. Endogenous carbon monoxide production in patients with hemolytic anemia. J Clin Invest 1966; 45:460.",
"     </a>",
"    </li>",
"    <li>",
"     Francis RB Jr, Hebbel RP. Hemostasis. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.299.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/54\">",
"      Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/55\">",
"      Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139:3.",
"     </a>",
"    </li>",
"    <li>",
"     Silverstein RL. The vascular endothelium. In: Inflammation: Basic Principles and Clinical Correlates, Gallin JI, Snyderman R (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.207.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/57\">",
"      Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/58\">",
"      Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003; 362:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/59\">",
"      Amer J, Ghoti H, Rachmilewitz E, et al. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 2006; 132:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/60\">",
"      Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/61\">",
"      Closse C, Seigneur M, Renard M, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res 1997; 85:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/62\">",
"      Setty BN, Chen D, O'Neal P, et al. Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion. J Lab Clin Med 1998; 131:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/63\">",
"      Schnog JB, Kater AP, Mac Gillavry MR, et al. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol 2001; 68:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/64\">",
"      Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/65\">",
"      Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007; :91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/66\">",
"      Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007; 98:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/67\">",
"      Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111:5271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/68\">",
"      Hebbel RP, Visser MR, Goodman JL, et al. Potentiated adherence of sickle erythrocytes to endothelium infected by virus. J Clin Invest 1987; 80:1503.",
"     </a>",
"    </li>",
"    <li>",
"     Lefer DJ, McLeod DS, Merges C, Lutty GA. Immunolocalization of ICAM-1 (CD 54) in the posterior eye of sickle cell and diabetic patients (abstr). Ophthal Vis Sci 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/70\">",
"      Wood K, Russell J, Hebbel RP, Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation 2004; 11:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/71\">",
"      Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005; 130:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/72\">",
"      Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 2010; 115:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/73\">",
"      Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010; 116:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/74\">",
"      Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011; 117:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/75\">",
"      Lebensburger JD, Howard T, Hu Y, et al. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood 2012; 119:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/76\">",
"      Kutlar A, Ataga KI, McMahon L, et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012; 87:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/77\">",
"      Tsai M, Kita A, Leach J, et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest 2012; 122:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/78\">",
"      Wood DK, Soriano A, Mahadevan L, et al. A biophysical indicator of vaso-occlusive risk in sickle cell disease. Sci Transl Med 2012; 4:123ra26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/79\">",
"      Abbyad P, Tharaux PL, Martin JL, et al. Sickling of red blood cells through rapid oxygen exchange in microfluidic drops. Lab Chip 2010; 10:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/80\">",
"      Manodori AB, Matsui NM, Chen JY, Embury SH. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood 1998; 92:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/81\">",
"      Manodori AB. Sickle erythrocytes adhere to fibronectin-thrombospondin-integrin complexes exposed by thrombin-induced endothelial cell contraction. Microvasc Res 2001; 61:263.",
"     </a>",
"    </li>",
"    <li>",
"     Embury SH, Matsui NM. Thrombin, endothelial gap formation, and eryhrocyte adhesion. In: Interactions of Blood and the Pulmonary Circulation, Weir EK, Reeve HL, Reeves JT (Eds), Futura Publishing Company, Inc., Armonk, NY 2002. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/83\">",
"      Chaplin H Jr, Monroe MC, Malecek AC, et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J 1989; 66:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/84\">",
"      Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/85\">",
"      Harlan JM. Introduction: anti-adhesion therapy in sickle cell disease. Blood 2000; 95:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/86\">",
"      Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997; 99:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/87\">",
"      Hebbel RP. Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med 2000; 342:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/88\">",
"      Jung U, Ley K. Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin. J Immunol 1999; 162:6755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/89\">",
"      Matsui NM, Borsig L, Rosen SD, et al. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood 2001; 98:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/90\">",
"      Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002; 100:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/91\">",
"      Embury SH, Matsui NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood 2004; 104:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/92\">",
"      Hidalgo A, Chang J, Jang JE, et al. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009; 15:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/93\">",
"      Kaul DK, Liu XD, Chang HY, et al. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 2004; 114:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/94\">",
"      Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/95\">",
"      Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995; 96:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/96\">",
"      Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood 2008; 112:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/97\">",
"      Werdehoff SG, Moore RB, Hoff CJ, et al. Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy. Am J Hematol 1998; 58:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/98\">",
"      Graido-Gonzalez E, Doherty JC, Bergreen EW, et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998; 92:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/99\">",
"      Hammerman SI, Kourembanas S, Conca TJ, et al. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 1997; 156:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/100\">",
"      Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 2008; 118:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/101\">",
"      Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010; 149:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/102\">",
"      Lapoum&eacute;roulie C, Benkerrou M, Odi&egrave;vre MH, et al. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. Haematologica 2005; 90:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/103\">",
"      Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997; 276:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/104\">",
"      Mondoro TH, Ryan BB, Hrinczenko BW, et al. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br J Haematol 2001; 112:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/105\">",
"      Space SL, Lane PA, Pickett CK, Weil JV. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol 2000; 63:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/106\">",
"      Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003; 9:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/107\">",
"      Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/108\">",
"      Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/109\">",
"      Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/110\">",
"      Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/111\">",
"      Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/112\">",
"      Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 2001; 98:15215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/113\">",
"      Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/114\">",
"      Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci U S A 2005; 102:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/115\">",
"      Taylor JG 6th, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3:e2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/116\">",
"      Kato GJ, Taylor JG 6th. Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol 2010; 148:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/117\">",
"      Zennadi R, Chien A, Xu K, et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008; 112:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/118\">",
"      Setty BN, Betal SG. Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes. Blood 2008; 111:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/119\">",
"      Zhou Z, Thiagarajan P, Udden M, et al. Erythrocyte membrane sulfatide plays a crucial role in the adhesion of sickle erythrocytes to endothelium. Thromb Haemost 2011; 105:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/120\">",
"      Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med 1980; 302:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/121\">",
"      Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992; 80:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/122\">",
"      Swerlick RA, Eckman JR, Kumar A, et al. Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993; 82:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/123\">",
"      Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood 2003; 101:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/124\">",
"      Zennadi R, Hines PC, De Castro LM, et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood 2004; 104:3774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/125\">",
"      Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007; 110:2708.",
"     </a>",
"    </li>",
"    <li>",
"     Chien S, Usami S, Skalak R. Blood flow in small tubes. In: Handbook of Physiology, Renkin EM, Michel CC, Geiger SR (Eds), American Physiological Society, Bethesda, MD 1993. p.217.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/127\">",
"      Lum AF, Wun T, Staunton D, Simon SI. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol 2004; 76:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/128\">",
"      Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/129\">",
"      Finnegan EM, Turhan A, Golan DE, Barabino GA. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion. Am J Hematol 2007; 82:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/130\">",
"      Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A 2002; 99:3047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/131\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/132\">",
"      Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998; 351:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/133\">",
"      Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \"switching\" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/134\">",
"      Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 2004; 104:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/135\">",
"      Krishnan S, Setty Y, Betal SG, et al. Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol 2010; 148:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/136\">",
"      Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/137\">",
"      Wun T, Paglieroni T, Tablin F, et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997; 129:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/138\">",
"      Greenberg J, Ohene-Frempong K, Halus J, et al. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr 1983; 102:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/139\">",
"      Cabannes R, Lonsdorfer J, Castaigne JP, et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/140\">",
"      PERILLIE PE, EPSTEIN FH. Sickling phenomenon produced by hypertonic solutions: a possible explanation for the hyposthenuria of sicklemia. J Clin Invest 1963; 42:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/141\">",
"      Bookchin RM, Balazs T, Landau LC. Determinants of red cell sickling. Effects of varying pH and of increasing intracellular hemoglobin concentration by osmotic shrinkage. J Lab Clin Med 1976; 87:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/142\">",
"      Masys DR, Bromberg PA, Balcerzak SP. Red cells shrink during sickling. Blood 1974; 44:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/143\">",
"      Gupta AK, Kirchner KA, Nicholson R, et al. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest 1991; 88:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/63/14330/abstract/144\">",
"      Yang YM, Donnell C, Wilborn W, et al. Splenic sequestration associated with sickle cell trait and hereditary spherocytosis. Am J Hematol 1992; 40:110.",
"     </a>",
"    </li>",
"    <li>",
"     Ballas SK. Sickle Cell Pain: Progress in Pain Research and Management, IASP Press, Seattle 1998. Vol 11.",
"    </li>",
"    <li>",
"     Treadwell MJ, Gil KM. Psychosocial aspects. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.517.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7135 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14330=[""].join("\n");
var outline_f13_63_14330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRADITIONAL POLYMER-BASED CONCEPTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sickling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Microvascular obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The steady state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MULTIPLE PATHWAY MODEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Microvascular transit time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Blood viscosity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dense irreversibly sickled cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other erythrocytic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coagulation, hemostasis, and platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Blood vessels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vascular endothelium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Matrix molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Vasoregulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sickle cell adhesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Leukocytes and inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7135|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/44/10945\" title=\"figure 1\">",
"      Vessel occlusion sickle cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/13/37075\" title=\"figure 2\">",
"      Sickle endothelial interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7135|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7135|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/19/15675\" title=\"table 1\">",
"      Contrib factors vasoocclusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17114?source=related_link\">",
"      Acute pain management in adults with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=related_link\">",
"      The endothelium: A primer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_63_14331="Dx possible MSA";
var content_f13_63_14331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for possible MSA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        A sporadic, progressive, adult (&gt;30 y)-onset disease characterized by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parkinsonism (bradykinesia with rigidity, tremor, or postural instability)",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction)",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary urgency, frequency or incomplete bladder emptying, erectile dysfunction in males, or significant orthostatic blood pressure decline that does not meet the level required in probable MSA)",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        At least one of the additional features shown in Table 3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSA: multiple system atrophy; y: year.",
"    </div>",
"    <div class=\"reference\">",
"     Gilman, S, Wenning, GK, Low, PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71:670.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14331=[""].join("\n");
var outline_f13_63_14331=null;
var title_f13_63_14332="Complete versus partial mole";
var content_f13_63_14332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinction between complete and partial molar pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Feature",
"      </td>",
"      <td class=\"subtitle1\">",
"       Complete mole",
"      </td>",
"      <td class=\"subtitle1\">",
"       Partial mole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Incidence",
"      </td>",
"      <td>",
"       1/1500 pregnancies",
"      </td>",
"      <td>",
"       1/750 pregnancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"      <td>",
"       Diploid: 46,XX (less than 15 percent are 46,XY)",
"      </td>",
"      <td>",
"       Triploid: 69,XXX, 69,XXY (rarely 69,XYY)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Embryonic/fetal tissue",
"      </td>",
"      <td>",
"       Typically absent (may be present in few cases)",
"      </td>",
"      <td>",
"       Present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Villi",
"      </td>",
"      <td>",
"       Diffusely hydropic",
"      </td>",
"      <td>",
"       Hydropic villi with marked scalloping mixed with normal appearing chorionic villi and fetal tissue; hydropic changes are focal and less prominent than in complete mole",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trophoblastic proliferation",
"      </td>",
"      <td>",
"       Hyperplastic",
"      </td>",
"      <td>",
"       Less trophoblastic hyperplasia than in complete mole; trophoblastic stromal inclusions can be seen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trophoblastic atypia",
"      </td>",
"      <td>",
"       Often present",
"      </td>",
"      <td>",
"       Infrequent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immuncoytochemistry",
"      </td>",
"      <td>",
"       hCG*, rare PLAP&bull;",
"      </td>",
"      <td>",
"       hcG, PLAP, p57",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uterine size",
"      </td>",
"      <td>",
"       Often large for dates",
"      </td>",
"      <td>",
"       Often small for dates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Theca lutein cysts",
"      </td>",
"      <td>",
"       Present in &le;25 percent",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Persistent mole",
"      </td>",
"      <td>",
"       15 to 20 percent",
"      </td>",
"      <td>",
"       3 to 5 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Choriocarcinoma",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       0.1 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Human chorionic gonadotropin.",
"     <br>",
"      &bull; Placental alkaline phosphatase.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Blaustein's Pathology of the Female Genital Tract, 4th ed, Kurman RJ (Ed), Springer-Verlag, New York, 1994, chapter 24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14332=[""].join("\n");
var outline_f13_63_14332=null;
var title_f13_63_14333="MELD three month survival";
var content_f13_63_14333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Estimated 3-month survival as a function of the MELD score in patients with cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 311px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MELD: model for end-stage liver disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wiesner, R, Edwards, E, Freeman, R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14333=[""].join("\n");
var outline_f13_63_14333=null;
var title_f13_63_14334="Sickle cell full evaluation";
var content_f13_63_14334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sickle cell disease - Routine comprehensive evaluations (in conjunction with a pediatric hematologist and/or sickle cell program)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age*",
"       </td>",
"       <td class=\"subtitle1\">",
"        History(ROS),&nbsp; Physical exam, Psychosocial assessment, Education",
"       </td>",
"       <td class=\"subtitle1\">",
"        CBC retic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hemoglobin electrophoresis",
"       </td>",
"       <td class=\"subtitle1\">",
"        RBC phenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chemistry",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        U/A",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pulse Ox",
"       </td>",
"       <td class=\"subtitle1\">",
"        CXR",
"       </td>",
"       <td class=\"subtitle1\">",
"        EKG echo PFT's",
"       </td>",
"       <td class=\"subtitle1\">",
"        CNS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gallbladder ultrasound",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ophth consult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18 months",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 9 years",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;10 years",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New patient",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table provides general guidelines; schedules for routine clinic visits and studies will need to be modified for individual patients.",
"    <div class=\"footnotes\">",
"     ROS: review of systems; CBC: complete blood count; Retic: reticulocyte count; RBC: red blood cell; U/A: urine analysis; Pulse Ox: Pulse oximetry (transcutaneous oxygen saturation); CXR: chest x-ray; EKG: electrocardiogram; Echo: echocardiogram; PFTs: pulmonary function testing; CNS: central nervous system.",
"     <br>",
"      * At EVERY age listed here it is important to initiate a discussion concerning treatment with hydroxyurea.",
"      <br>",
"       &bull; Consider creatinine, blood urea nitrogen (BUN), liver function tests. Consider adding ferritin and/or iron and total iron binding capacity (TIBC) for any patients at risk for iron deficiency or for those at risk for hemosiderosis secondary to multiple transfusions.",
"       <br>",
"        1. Patients without documented confirmation of diagnostic testing or for whom diagnosis is unclear (eg, FS or FSA on neonatal screen without subsequent anemia or hemolysis); review of other hematologic studies and family studies may also help establish accurate diagnosis.",
"        <br>",
"         2.&nbsp;Two to&nbsp;three times per year.",
"         <br>",
"          3. Yearly.",
"          <br>",
"           4. Consider every other year; yearly if history of recent acute chest syndrome or evidence of chronic cardiac or pulmonary disease.",
"           <br>",
"            5. Consider to document baseline status and evidence of chronic cardiac or pulmonary disease in patients with history of severe or recurrent acute chest syndrome or unexplained cardiopulmonary symptoms.",
"            <br>",
"             6. May include CNS imaging such as magnetic resonance imaging (MRI),&nbsp;magnetic resonance angiography (MRA), and transcranial doppler (TCD) ultrasonography and/or neurocognitive testing. Consider especially for patients with poor school performance or developmental or behavioral concerns.",
"             <br>",
"              7. prn clinical suspicion of cholelithiasis.",
"              <br>",
"               8. Every&nbsp;one to two&nbsp;years.",
"               <br>",
"                9. As appropriate for age.",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sickle cell disease in children and adolescents: Diagnosis, guidelines for comprehensive care, and care paths and protocols for management of acute and chronic complications. Revised at the Annual Meeting of the Sickle Cell Disease Care Consortium, Sedona, AZ, November 10-12, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14334=[""].join("\n");
var outline_f13_63_14334=null;
var title_f13_63_14335="DDx of rash by appearance 1";
var content_f13_63_14335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52167%7EID%2F63955%7EID%2F71663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52167%7EID%2F63955%7EID%2F71663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon appearance of the rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macules, papules, nodules, or plaques",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vesicles, bullae, or pustules",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpuric macules, purpuric papules, or purpuric vesicles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Followed widespread erythema with or without edema by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Arcanobacterium haemolyticum",
"        </p>",
"        <p>",
"         Bacillus anthracis",
"        </p>",
"        <p>",
"         Bartonella bacilliformis",
"        </p>",
"        <p>",
"         Bartonella henselae (cat scratch disease)",
"        </p>",
"        <p>",
"         Bartonella quintana (trench fever)",
"        </p>",
"        <p>",
"         Borrelia burgdorferi (Lyme disease)*",
"        </p>",
"        <p>",
"         Borrelia spp (relapsing fever)",
"        </p>",
"        <p>",
"         Brucella spp (brucellosis)*",
"        </p>",
"        <p>",
"         Calymmatobacterium granulomatis (donovanosis)*",
"        </p>",
"        <p>",
"         Chlamydia psittaci (psittacosis)",
"        </p>",
"        <p>",
"         Ehrlichiosis*",
"        </p>",
"        <p>",
"         Ehrlichia chafeensis (HME)",
"        </p>",
"        <p>",
"         Human granulocytic erlichiosis (HGE)",
"        </p>",
"        <p>",
"         Erypsipelothrix rhusiopathiae (erysipeloid)",
"        </p>",
"        <p>",
"         Francisella tularensis (tularemia)",
"        </p>",
"        <p>",
"         Listeria monocytogenes",
"        </p>",
"        <p>",
"         Leptospira sp (leptospirosis)*",
"        </p>",
"        <p>",
"         Mycobacterium leprae*",
"        </p>",
"        <p>",
"         Mycobacterium marinum*",
"        </p>",
"        <p>",
"         Mycobacterium tuberculosis",
"        </p>",
"        <p>",
"         Mycoplasma pneumoniae",
"        </p>",
"        <p>",
"         Neisseria gonorrhoeae (gonorrhea)*",
"        </p>",
"        <p>",
"         Neisseria meningitidis (meningococcemia)*",
"        </p>",
"        <p>",
"         Pseudomonas aeruginosa",
"        </p>",
"        <p>",
"         Rickettsia akari (rickettsialpox)",
"        </p>",
"        <p>",
"         Rickettsia prowazekii (epidemic/louse- borne typhus)",
"        </p>",
"        <p>",
"         Rickettsia rickettsii (RMSF-early lesions)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Rickettsia orientalis/tsutsugamushi (scrub typhus)",
"        </p>",
"        <p>",
"         Rickettsia typhi (endemic/murine typhus)",
"        </p>",
"        <p>",
"         Salmonella typhi (typhoid fever)*",
"        </p>",
"        <p>",
"         Spirillum minor (rat-bite fever)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bacillus anthracis",
"        </p>",
"        <p>",
"         Ehrlichia canis",
"        </p>",
"        <p>",
"         Listeria monocytogenes",
"        </p>",
"        <p>",
"         Mycoplasma pneumoniae",
"        </p>",
"        <p>",
"         Neisseria gonorrhoeae*",
"        </p>",
"        <p>",
"         Neisseria meningitidis*",
"        </p>",
"        <p>",
"         Pseudomonas aeruginosa",
"        </p>",
"        <p>",
"         Rickettsia akari",
"        </p>",
"        <p>",
"         Rickettsia rickettsii*",
"        </p>",
"        <p>",
"         Staphylococcus aureus (TSS, SSSS)",
"        </p>",
"        <p>",
"         Streptococcus group A",
"        </p>",
"        <p>",
"         Treponema pallidum (secondary syphilis)",
"        </p>",
"        <p>",
"         Vibrio vulnificus",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bacteremia",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Borrelia spp",
"        </p>",
"        <p>",
"         Clostridium spp",
"        </p>",
"        <p>",
"         Infective endocarditis (many species)",
"        </p>",
"        <p>",
"         Haemophilus influenzae type B",
"        </p>",
"        <p>",
"         Neisseria gonorrhoeae (disseminated gonococcal infection)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Neisseria meningitidis (acute or chronic meningococcemia)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Pseudomonas aeruginosa",
"        </p>",
"        <p>",
"         Rickettsia prowazekii",
"        </p>",
"        <p>",
"         Rickettsia rickettsii",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Spirillum minor",
"        </p>",
"        <p>",
"         Staphylococcus aureus (bacteremia)",
"        </p>",
"        <p>",
"         Streptobacillus moniliformis",
"        </p>",
"        <p>",
"         Streptococcus group A (streptococcal toxic shock syndrome, scarlet fever)",
"        </p>",
"        <p>",
"         Streptococcus pneumoniae (asplenic patient)",
"        </p>",
"        <p>",
"         Vibrio vulnificus",
"        </p>",
"        <p>",
"         Yersinia pestis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Streptococcus group A (scarlet fever, streptococcal toxic shock syndrome)",
"        </p>",
"        <p>",
"         Stapylococcus aureus (toxic shock syndrome [TSS], scalded skin syndrome [SSSS])",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reportable disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May have arthralgia or musculoskeletal pain.",
"      <br>",
"       &Delta; Specific therapy available.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon appearance of the rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macules, papules, nodules, or plaques",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vesicles, bullae, or pustules",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpuric macules, purpuric papules, or purpuric vesicles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Widespread erythema with or without edema followed by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Blastomyces dermatitidis*",
"        </p>",
"        <p>",
"         Candida spp",
"        </p>",
"        <p>",
"         Coccidioides immitis",
"        </p>",
"        <p>",
"         Cryptococcus neoformans",
"        </p>",
"        <p>",
"         Histoplasma capsulatum",
"        </p>",
"        <p>",
"         Other disseminated deep fungal infections in immunocompromised patients",
"        </p>",
"       </td>",
"       <td>",
"        Histoplasma capsulatum",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Arbovirus",
"        </p>",
"        <p>",
"         Atypical measles*",
"        </p>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Coxsackieviruses A and B",
"        </p>",
"        <p>",
"         Cytomegalovirus, primary infection",
"        </p>",
"        <p>",
"         Dengue virus",
"        </p>",
"        <p>",
"         Epstein-Barr virus, primary infection",
"        </p>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Hepatitis B (urticaria)*",
"        </p>",
"        <p>",
"         Human herpesvirus 6 (exanthem subitum)*",
"        </p>",
"        <p>",
"         Human immunodeficiency virus (HIV-1)*",
"        </p>",
"        <p>",
"         Kawasaki syndrome (presumed viral)",
"        </p>",
"        <p>",
"         Molluscum contagiosum",
"        </p>",
"        <p>",
"         Orf",
"        </p>",
"        <p>",
"         Parvovirus B19 (erythema infectiosum {fifth disease})",
"        </p>",
"        <p>",
"         Rubella (German measles)*",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Rubeola (measles)*",
"        </p>",
"        <p>",
"         Varicella (chickenpox)*",
"        </p>",
"        <p>",
"         Varicella zoster (disseminated)",
"        </p>",
"        <p>",
"         Viral hemorrhagic fevers (many)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Coxsackie A5, 9, 10, 16, B2, 7",
"        </p>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Eczema herpeticum",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Herpes simplex (disseminated)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Varicella (chickenpox)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Varicella-zoster (disseminated)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Adenovirus (rare)",
"        </p>",
"        <p>",
"         Atypical measles*",
"        </p>",
"        <p>",
"         Colorado tick fever",
"        </p>",
"        <p>",
"         Congenital cytomegalovirus",
"        </p>",
"        <p>",
"         Coxsackie A and B (rare, types A-9, B2-5)",
"        </p>",
"        <p>",
"         Dengue fever",
"        </p>",
"        <p>",
"         Epstein-Barr virus (rare)",
"        </p>",
"        <p>",
"         Echoviruses (rare, types 3, 4, 9)",
"        </p>",
"        <p>",
"         Rubella*",
"        </p>",
"        <p>",
"         Varicella zoster virus",
"        </p>",
"        <p>",
"         Yellow fever",
"        </p>",
"       </td>",
"       <td>",
"        Kawasaki syndrome (presumed viral)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reportable disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      May have arthralgia or musculoskeletal pain.",
"      <br>",
"       &Delta; Umbilicated papule or vesicle a characteristic of these exanthems.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon appearance of the rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macules, papules, nodules, or plaques",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vesicles, bullae, or pustules",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpuric macules, purpuric papules, or purpuric vesicles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Widespread erythema with or without edema followed by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Protozoal/parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Leishmania braziliensis",
"        </p>",
"        <p>",
"         Leishmania mexicana",
"        </p>",
"        <p>",
"         Leishmania tropica",
"        </p>",
"        <p>",
"         Necator americanus",
"        </p>",
"        <p>",
"         Onchocerca volvulus",
"        </p>",
"        <p>",
"         Schistosoma",
"        </p>",
"        <p>",
"         Strongyloides stercoralis",
"        </p>",
"        <p>",
"         Toxoplasma gondii (toxoplasmosis)",
"        </p>",
"        <p>",
"         Trichinella spiralis (trichinosis)",
"        </p>",
"        <p>",
"         Trypanosoma sp.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Plasmodium falciparum (blackwater fever)*",
"        </p>",
"        <p>",
"         Trichinella spiralis (trichinosis)",
"        </p>",
"        <p>",
"         Toxoplasma gondii",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Noninfectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Erythema multiforme",
"        </p>",
"        <p>",
"         Systemic lupus erythematosus",
"        </p>",
"        <p>",
"         Dermatomyositis",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Gianotti-Crosti syndrome",
"        </p>",
"        <p>",
"         Inflammatory bowel disease",
"        </p>",
"        <p>",
"         Pityriasis rosea (fever rare)",
"        </p>",
"        <p>",
"         Sarcoidosis",
"        </p>",
"        <p>",
"         \"Serum sickness\"",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Sweet's syndrome (acute febrile neutrophilic dermatosis)",
"        </p>",
"        <p>",
"         Still's disease (juvenile idiopathic arthritis)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythema multiforme bullosum",
"        </p>",
"        <p>",
"         Toxic epidermal necrolysis",
"        </p>",
"        <p>",
"         Dermatitis from plants",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         \"Allergic\" vasculitis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Erythroderma",
"        </p>",
"        <p>",
"         Cholesterol embolization",
"        </p>",
"        <p>",
"         Disseminated intravascular coagulation (purpura fulminans)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Fat embolism",
"        </p>",
"        <p>",
"         Henoch-Sch&ouml;nlein purpura",
"        </p>",
"        <p>",
"         Immune thrombocytopenic purpura",
"        </p>",
"        <p>",
"         Granulomatosis with polyangiitis (Wegener's)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythroderma",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Graft-versus-host reaction",
"        </p>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Toxic epidermal necrolysis",
"        </p>",
"        <p>",
"         von Zumbusch pustular psoriasis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reportable disease.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     May have arthralgia or musculoskeletal pain.",
"     <br/>",
"     &Delta; Often present as infarcts.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from: Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_63_14335=[""].join("\n");
var outline_f13_63_14335=null;
